KEGG   Homo sapiens (human): 1956
Entry
1956              CDS       T01001                                 
Symbol
EGFR, ERBB, ERBB1, ERRP, HER1, NISBD2, PIG61, mENA
Name
(RefSeq) epidermal growth factor receptor
  KO
K04361  epidermal growth factor receptor [EC:2.7.10.1]
Organism
hsa  Homo sapiens (human)
Pathway
hsa01521  EGFR tyrosine kinase inhibitor resistance
hsa01522  Endocrine resistance
hsa04010  MAPK signaling pathway
hsa04012  ErbB signaling pathway
hsa04014  Ras signaling pathway
hsa04015  Rap1 signaling pathway
hsa04020  Calcium signaling pathway
hsa04066  HIF-1 signaling pathway
hsa04068  FoxO signaling pathway
hsa04072  Phospholipase D signaling pathway
hsa04144  Endocytosis
hsa04151  PI3K-Akt signaling pathway
hsa04510  Focal adhesion
hsa04520  Adherens junction
hsa04540  Gap junction
hsa04630  JAK-STAT signaling pathway
hsa04810  Regulation of actin cytoskeleton
hsa04912  GnRH signaling pathway
hsa04915  Estrogen signaling pathway
hsa04921  Oxytocin signaling pathway
hsa04926  Relaxin signaling pathway
hsa04928  Parathyroid hormone synthesis, secretion and action
hsa04934  Cushing syndrome
hsa05120  Epithelial cell signaling in Helicobacter pylori infection
hsa05131  Shigellosis
hsa05160  Hepatitis C
hsa05163  Human cytomegalovirus infection
hsa05165  Human papillomavirus infection
hsa05171  Coronavirus disease - COVID-19
hsa05200  Pathways in cancer
hsa05205  Proteoglycans in cancer
hsa05206  MicroRNAs in cancer
hsa05207  Chemical carcinogenesis - receptor activation
hsa05208  Chemical carcinogenesis - reactive oxygen species
hsa05210  Colorectal cancer
hsa05212  Pancreatic cancer
hsa05213  Endometrial cancer
hsa05214  Glioma
hsa05215  Prostate cancer
hsa05218  Melanoma
hsa05219  Bladder cancer
hsa05223  Non-small cell lung cancer
hsa05224  Breast cancer
hsa05225  Hepatocellular carcinoma
hsa05226  Gastric cancer
hsa05230  Central carbon metabolism in cancer
hsa05231  Choline metabolism in cancer
hsa05235  PD-L1 expression and PD-1 checkpoint pathway in cancer
Network
nt06110  MAPK signaling (viruses and bacteria)
nt06114  PI3K signaling (viruses)
nt06120  Calcium signaling (viruses and bacteria)
nt06135  Cytoskeletal regulation (viruses and bacteria)
nt06160  Human T-cell leukemia virus 1 (HTLV-1)
nt06162  Hepatitis B virus (HBV)
nt06163  Hepatitis C virus (HCV)
nt06164  Kaposi sarcoma-associated herpesvirus (KSHV)
nt06165  Epstein-Barr virus (EBV)
nt06166  Human papillomavirus (HPV)
nt06167  Human cytomegalovirus (HCMV)
nt06170  Influenza A virus (IAV)
nt06210  ERK signaling
nt06213  Other RAS signaling
nt06214  PI3K signaling
nt06219  JAK-STAT signaling
nt06220  Calcium signaling
nt06260  Colorectal cancer
nt06261  Gastric cancer
nt06262  Pancreatic cancer
nt06263  Hepatocellular carcinoma
nt06265  Bladder cancer
nt06266  Non-small cell lung cancer
nt06268  Melanoma
nt06270  Breast cancer
nt06271  Endometrial cancer
nt06273  Glioma
nt06274  Thyroid cancer
nt06276  Chronic myeloid leukemia
nt06310  CRH-ACTH-cortisol signaling
nt06360  Cushing syndrome
  Element
N00001  EGF-EGFR-RAS-ERK signaling pathway
N00006  Amplified EGFR to RAS-ERK signaling pathway
N00014  Mutation-activated EGFR to RAS-ERK signaling pathway
N00021  EGF-ERBB2-RAS-ERK signaling pathway
N00022  ERBB2-overexpression to RAS-ERK signaling pathway
N00023  EGF-EGFR-PLCG-ERK signaling pathway
N00024  Mutation-activated EGFR to PLCG-ERK signaling pathway
N00026  EGF-EGFR-PLCG-CAMK signaling pathway
N00027  Amplified EGFR to PLCG-CAMK signaling pathway
N00030  EGF-EGFR-RAS-PI3K signaling pathway
N00033  EGF-EGFR-PI3K signaling pathway
N00034  ERBB2-overexpression to PI3K signaling pathway
N00035  Amplified EGFR to PI3K signaling pathway
N00036  Mutation-activated EGFR to PI3K signaling pathway
N00041  EGFR-overexpression to RAS-ERK signaling pathway
N00042  EGFR-overexpression to PI3K signaling pathway
N00094  EGF-Jak-STAT signaling pathway
N00095  ERBB2-overexpression to EGF-Jak-STAT signaling pathway
N00096  EGF-EGFR-RAS-RASSF1 signaling pathway
N00103  EGF-EGFR-RAS-RalGDS signaling pathway
N00147  EGF-EGFR-PLCG-calcineurin signaling pathway
N00227  TGFA-EGFR-PLCG-PKC signaling pathway
N00228  TGFA-overexpression to PLCG-PKC signaling pathway
N00229  TGFA-EGFR-RAS-ERK signaling pathway
N00230  TGFA-overexpression to RAS-ERK signaling pathway
N00231  TGFA-EGFR-PI3K signaling pathway
N00232  TGFA-overexpression to PI3K signaling pathway
N00252  Amplified ERBB2 to RAS-ERK signaling pathway
N00253  Amplified ERBB2 to PI3K signaling pathway
N00276  EGF-overexpression to RAS-ERK signaling pathway
N00277  EREG-EGFR-RAS-ERK signaling pathway
N00278  EREG-overexpression to RAS-ERK signaling pathway
N00279  AREG-EGFR-RAS-ERK signaling pathway
N00280  AREG-overexpression to RAS-ERK signaling pathway
N00281  EGF-overexpression to PI3K signaling pathway
N00282  EREG-EGFR-PI3K signaling pathway
N00283  EREG-overexpression to PI3K signaling pathway
N00284  AREG-EGFR-PI3K signaling pathway
N00285  AREG-overexpression to PI3K signaling pathway
N00318  EGFR-ERK-ACTH signaling pathway
N00319  Mutation-activated USP8 to EGFR-ERK-ACTH signaling pathway
N00366  HPV E5 to EGFR-PI3K signaling pathway
N00367  HPV E5 to EGFR-RAS-ERK signaling pathway
N00390  EGF-EGFR-PI3K-NFKB signaling pathway
N00391  HCMV gB to EGFR-PI3K-NFKB signaling pathway
N00392  HCMV gB to EGFR-RAS-ERK signaling pathway
N00513  Mutation-activated EGFR to RAS-ERK signaling pathway
N00514  Mutation-activated EGFR to PI3K signaling pathway
N00542  EGF-EGFR-RAS-JNK signaling pathway
N01078  EGF-EGFR-Actin signaling pathway
N01354  BPA to RAS-ERK signaling pathway
N01355  Arsenic to PI3K signaling pathway
N10005  First/second-generation tyrosine kinase inhibitor to EGFR mutation
N10006  Third-generation tyrosine kinase inhibitor to EGFR mutation
Disease
H00014  Non-small cell lung cancer
H00016  Oral cancer
H00017  Esophageal cancer
H00022  Bladder cancer
H00028  Choriocarcinoma
H00030  Cervical cancer
H00031  Breast cancer
H00042  Glioma
H00055  Laryngeal cancer
H01508  Salivary gland cancer
H01559  Oropharyngeal cancer
H02467  Neonatal inflammatory skin and bowel disease
Drug target
Afatinib (DG00717): D09724 D09733<JP/US>
Amivantamab: D11894<US> D11894<US>
Aumolertinib (DG03209): D12258 D12259
Canertinib dihydrochloride: D03350
Cetuximab: D03455<JP/US>
Cetuximab sarotalocan: D11803
Cetuximab sarotalocan sodium: D11805<JP>
Dacomitinib (DG01793): D09883 D10514<JP/US>
Duligotuzumab: D11750
Erlotinib (DG00711): D04023<JP/US> D07907
Gefitinib: D01977<JP/US>
Icotinib: D11251
Imgatuzumab: D10439
Lapatinib (DG00715): D04024<JP/US> D08108
Lazertinib (DG03205): D11980 D12245
Lifirafenib (DG03009): D11410 D11411
Masoprocol: D04862
Mavelertinib: D11368
Mobocertinib (DG03148): D11969<US> D12001
Modotuximab: D11125
Naquotinib (DG03112): D10886 D10958
Nazartinib (DG03015): D11430 D11434
Necitumumab: D10018<JP/US>
Neratinib (DG02303): D08950 D10898<US>
Olmutinib (DG02916): D10859 D11115
Osimertinib: D10766<JP/US>
Panitumumab: D05350<JP/US>
Pelitinib: D05399
Poziotinib (DG03196): D12229 D12230
Rindopepimut: D09660
Rociletinib: D10858
Serclutamab: D11872
Serclutamab talirine: D11874
Tesevatinib (DG03101): D11772 D11773
Vandetanib: D06407<JP/US>
Varlitinib (DG01357): D09689 D09690
Zalutumumab: D10031
Brite
KEGG Orthology (KO) [BR:hsa00001]
 09130 Environmental Information Processing
  09132 Signal transduction
   04010 MAPK signaling pathway
    1956 (EGFR)
   04012 ErbB signaling pathway
    1956 (EGFR)
   04014 Ras signaling pathway
    1956 (EGFR)
   04015 Rap1 signaling pathway
    1956 (EGFR)
   04630 JAK-STAT signaling pathway
    1956 (EGFR)
   04066 HIF-1 signaling pathway
    1956 (EGFR)
   04068 FoxO signaling pathway
    1956 (EGFR)
   04020 Calcium signaling pathway
    1956 (EGFR)
   04072 Phospholipase D signaling pathway
    1956 (EGFR)
   04151 PI3K-Akt signaling pathway
    1956 (EGFR)
 09140 Cellular Processes
  09141 Transport and catabolism
   04144 Endocytosis
    1956 (EGFR)
  09144 Cellular community - eukaryotes
   04510 Focal adhesion
    1956 (EGFR)
   04520 Adherens junction
    1956 (EGFR)
   04540 Gap junction
    1956 (EGFR)
  09142 Cell motility
   04810 Regulation of actin cytoskeleton
    1956 (EGFR)
 09150 Organismal Systems
  09152 Endocrine system
   04912 GnRH signaling pathway
    1956 (EGFR)
   04915 Estrogen signaling pathway
    1956 (EGFR)
   04921 Oxytocin signaling pathway
    1956 (EGFR)
   04926 Relaxin signaling pathway
    1956 (EGFR)
   04928 Parathyroid hormone synthesis, secretion and action
    1956 (EGFR)
 09160 Human Diseases
  09161 Cancer: overview
   05200 Pathways in cancer
    1956 (EGFR)
   05206 MicroRNAs in cancer
    1956 (EGFR)
   05205 Proteoglycans in cancer
    1956 (EGFR)
   05207 Chemical carcinogenesis - receptor activation
    1956 (EGFR)
   05208 Chemical carcinogenesis - reactive oxygen species
    1956 (EGFR)
   05230 Central carbon metabolism in cancer
    1956 (EGFR)
   05231 Choline metabolism in cancer
    1956 (EGFR)
   05235 PD-L1 expression and PD-1 checkpoint pathway in cancer
    1956 (EGFR)
  09162 Cancer: specific types
   05210 Colorectal cancer
    1956 (EGFR)
   05212 Pancreatic cancer
    1956 (EGFR)
   05225 Hepatocellular carcinoma
    1956 (EGFR)
   05226 Gastric cancer
    1956 (EGFR)
   05214 Glioma
    1956 (EGFR)
   05218 Melanoma
    1956 (EGFR)
   05219 Bladder cancer
    1956 (EGFR)
   05215 Prostate cancer
    1956 (EGFR)
   05213 Endometrial cancer
    1956 (EGFR)
   05224 Breast cancer
    1956 (EGFR)
   05223 Non-small cell lung cancer
    1956 (EGFR)
  09172 Infectious disease: viral
   05160 Hepatitis C
    1956 (EGFR)
   05171 Coronavirus disease - COVID-19
    1956 (EGFR)
   05163 Human cytomegalovirus infection
    1956 (EGFR)
   05165 Human papillomavirus infection
    1956 (EGFR)
  09171 Infectious disease: bacterial
   05120 Epithelial cell signaling in Helicobacter pylori infection
    1956 (EGFR)
   05131 Shigellosis
    1956 (EGFR)
  09167 Endocrine and metabolic disease
   04934 Cushing syndrome
    1956 (EGFR)
  09176 Drug resistance: antineoplastic
   01521 EGFR tyrosine kinase inhibitor resistance
    1956 (EGFR)
   01522 Endocrine resistance
    1956 (EGFR)
 09180 Brite Hierarchies
  09181 Protein families: metabolism
   01001 Protein kinases [BR:hsa01001]
    1956 (EGFR)
  09183 Protein families: signaling and cellular processes
   04147 Exosome [BR:hsa04147]
    1956 (EGFR)
Enzymes [BR:hsa01000]
 2. Transferases
  2.7  Transferring phosphorus-containing groups
   2.7.10  Protein-tyrosine kinases
    2.7.10.1  receptor protein-tyrosine kinase
     1956 (EGFR)
Protein kinases [BR:hsa01001]
 Receptor tyrosine kinases (RTK)
  EGFR family [OT]
   1956 (EGFR)
Exosome [BR:hsa04147]
 Exosomal proteins
  Exosomal proteins of colorectal cancer cells
   1956 (EGFR)
  Exosomal proteins of pancreatic cancer cells
   1956 (EGFR)
  Exosomal proteins of bladder cancer cells
   1956 (EGFR)
SSDB
Motif
Pfam: PK_Tyr_Ser-Thr Recep_L_domain GF_recep_IV Pkinase Furin-like Kinase-like APH GAPT ABC1 Kdo
Other DBs
NCBI-GeneID: 1956
NCBI-ProteinID: NP_005219
OMIM: 131550
HGNC: 3236
Ensembl: ENSG00000146648
Pharos: P00533(Tclin)
UniProt: P00533 Q504U8 F2YGG7
Structure
LinkDB
Position
7:55019017..55211628
AA seq 1210 aa
MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEV
VLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALA
VLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDF
QNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGC
TGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYV
VTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFK
NCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAF
ENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKL
FGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCN
LLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM
GENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVV
ALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGS
GAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGI
CLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAA
RNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSY
GVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPK
FRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQ
QGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTED
SIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLN
TVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRV
APQSSEFIGA
NT seq 3633 nt   +upstreamnt  +downstreamnt
atgcgaccctccgggacggccggggcagcgctcctggcgctgctggctgcgctctgcccg
gcgagtcgggctctggaggaaaagaaagtttgccaaggcacgagtaacaagctcacgcag
ttgggcacttttgaagatcattttctcagcctccagaggatgttcaataactgtgaggtg
gtccttgggaatttggaaattacctatgtgcagaggaattatgatctttccttcttaaag
accatccaggaggtggctggttatgtcctcattgccctcaacacagtggagcgaattcct
ttggaaaacctgcagatcatcagaggaaatatgtactacgaaaattcctatgccttagca
gtcttatctaactatgatgcaaataaaaccggactgaaggagctgcccatgagaaattta
caggaaatcctgcatggcgccgtgcggttcagcaacaaccctgccctgtgcaacgtggag
agcatccagtggcgggacatagtcagcagtgactttctcagcaacatgtcgatggacttc
cagaaccacctgggcagctgccaaaagtgtgatccaagctgtcccaatgggagctgctgg
ggtgcaggagaggagaactgccagaaactgaccaaaatcatctgtgcccagcagtgctcc
gggcgctgccgtggcaagtcccccagtgactgctgccacaaccagtgtgctgcaggctgc
acaggcccccgggagagcgactgcctggtctgccgcaaattccgagacgaagccacgtgc
aaggacacctgccccccactcatgctctacaaccccaccacgtaccagatggatgtgaac
cccgagggcaaatacagctttggtgccacctgcgtgaagaagtgtccccgtaattatgtg
gtgacagatcacggctcgtgcgtccgagcctgtggggccgacagctatgagatggaggaa
gacggcgtccgcaagtgtaagaagtgcgaagggccttgccgcaaagtgtgtaacggaata
ggtattggtgaatttaaagactcactctccataaatgctacgaatattaaacacttcaaa
aactgcacctccatcagtggcgatctccacatcctgccggtggcatttaggggtgactcc
ttcacacatactcctcctctggatccacaggaactggatattctgaaaaccgtaaaggaa
atcacagggtttttgctgattcaggcttggcctgaaaacaggacggacctccatgccttt
gagaacctagaaatcatacgcggcaggaccaagcaacatggtcagttttctcttgcagtc
gtcagcctgaacataacatccttgggattacgctccctcaaggagataagtgatggagat
gtgataatttcaggaaacaaaaatttgtgctatgcaaatacaataaactggaaaaaactg
tttgggacctccggtcagaaaaccaaaattataagcaacagaggtgaaaacagctgcaag
gccacaggccaggtctgccatgccttgtgctcccccgagggctgctggggcccggagccc
agggactgcgtctcttgccggaatgtcagccgaggcagggaatgcgtggacaagtgcaac
cttctggagggtgagccaagggagtttgtggagaactctgagtgcatacagtgccaccca
gagtgcctgcctcaggccatgaacatcacctgcacaggacggggaccagacaactgtatc
cagtgtgcccactacattgacggcccccactgcgtcaagacctgcccggcaggagtcatg
ggagaaaacaacaccctggtctggaagtacgcagacgccggccatgtgtgccacctgtgc
catccaaactgcacctacggatgcactgggccaggtcttgaaggctgtccaacgaatggg
cctaagatcccgtccatcgccactgggatggtgggggccctcctcttgctgctggtggtg
gccctggggatcggcctcttcatgcgaaggcgccacatcgttcggaagcgcacgctgcgg
aggctgctgcaggagagggagcttgtggagcctcttacacccagtggagaagctcccaac
caagctctcttgaggatcttgaaggaaactgaattcaaaaagatcaaagtgctgggctcc
ggtgcgttcggcacggtgtataagggactctggatcccagaaggtgagaaagttaaaatt
cccgtcgctatcaaggaattaagagaagcaacatctccgaaagccaacaaggaaatcctc
gatgaagcctacgtgatggccagcgtggacaacccccacgtgtgccgcctgctgggcatc
tgcctcacctccaccgtgcagctcatcacgcagctcatgcccttcggctgcctcctggac
tatgtccgggaacacaaagacaatattggctcccagtacctgctcaactggtgtgtgcag
atcgcaaagggcatgaactacttggaggaccgtcgcttggtgcaccgcgacctggcagcc
aggaacgtactggtgaaaacaccgcagcatgtcaagatcacagattttgggctggccaaa
ctgctgggtgcggaagagaaagaataccatgcagaaggaggcaaagtgcctatcaagtgg
atggcattggaatcaattttacacagaatctatacccaccagagtgatgtctggagctac
ggggtgactgtttgggagttgatgacctttggatccaagccatatgacggaatccctgcc
agcgagatctcctccatcctggagaaaggagaacgcctccctcagccacccatatgtacc
atcgatgtctacatgatcatggtcaagtgctggatgatagacgcagatagtcgcccaaag
ttccgtgagttgatcatcgaattctccaaaatggcccgagacccccagcgctaccttgtc
attcagggggatgaaagaatgcatttgccaagtcctacagactccaacttctaccgtgcc
ctgatggatgaagaagacatggacgacgtggtggatgccgacgagtacctcatcccacag
cagggcttcttcagcagcccctccacgtcacggactcccctcctgagctctctgagtgca
accagcaacaattccaccgtggcttgcattgatagaaatgggctgcaaagctgtcccatc
aaggaagacagcttcttgcagcgatacagctcagaccccacaggcgccttgactgaggac
agcatagacgacaccttcctcccagtgcctgaatacataaaccagtccgttcccaaaagg
cccgctggctctgtgcagaatcctgtctatcacaatcagcctctgaaccccgcgcccagc
agagacccacactaccaggacccccacagcactgcagtgggcaaccccgagtatctcaac
actgtccagcccacctgtgtcaacagcacattcgacagccctgcccactgggcccagaaa
ggcagccaccaaattagcctggacaaccctgactaccagcaggacttctttcccaaggaa
gccaagccaaatggcatctttaagggctccacagctgaaaatgcagaatacctaagggtc
gcgccacaaagcagtgaatttattggagcatga

KEGG   Homo sapiens (human): 2064
Entry
2064              CDS       T01001                                 
Symbol
ERBB2, CD340, HER-2, HER-2/neu, HER2, MLN_19, NEU, NGL, TKR1, VSCN2, c-ERB-2, c-ERB2
Name
(RefSeq) erb-b2 receptor tyrosine kinase 2
  KO
K05083  receptor tyrosine-protein kinase erbB-2 [EC:2.7.10.1]
Organism
hsa  Homo sapiens (human)
Pathway
hsa01521  EGFR tyrosine kinase inhibitor resistance
hsa01522  Endocrine resistance
hsa01524  Platinum drug resistance
hsa04010  MAPK signaling pathway
hsa04012  ErbB signaling pathway
hsa04020  Calcium signaling pathway
hsa04066  HIF-1 signaling pathway
hsa04151  PI3K-Akt signaling pathway
hsa04510  Focal adhesion
hsa04520  Adherens junction
hsa04530  Tight junction
hsa05200  Pathways in cancer
hsa05205  Proteoglycans in cancer
hsa05206  MicroRNAs in cancer
hsa05212  Pancreatic cancer
hsa05213  Endometrial cancer
hsa05215  Prostate cancer
hsa05219  Bladder cancer
hsa05223  Non-small cell lung cancer
hsa05224  Breast cancer
hsa05226  Gastric cancer
hsa05230  Central carbon metabolism in cancer
Network
nt06210  ERK signaling
nt06214  PI3K signaling
nt06216  NOTCH signaling
nt06219  JAK-STAT signaling
nt06261  Gastric cancer
nt06262  Pancreatic cancer
nt06265  Bladder cancer
nt06266  Non-small cell lung cancer
nt06270  Breast cancer
  Element
N00021  EGF-ERBB2-RAS-ERK signaling pathway
N00022  ERBB2-overexpression to RAS-ERK signaling pathway
N00034  ERBB2-overexpression to PI3K signaling pathway
N00087  NOTCH-overexpression to Notch signaling pathway
N00095  ERBB2-overexpression to EGF-Jak-STAT signaling pathway
N00252  Amplified ERBB2 to RAS-ERK signaling pathway
N00253  Amplified ERBB2 to PI3K signaling pathway
N10009  Tyrosine kinase inhibitor to HER2 overexpression/amplification
Disease
H00018  Gastric cancer
H00019  Pancreatic cancer
H00022  Bladder cancer
H00026  Endometrial cancer
H00027  Ovarian cancer
H00028  Choriocarcinoma
H00030  Cervical cancer
H00031  Breast cancer
H00042  Glioma
H00046  Cholangiocarcinoma
H01508  Salivary gland cancer
H01554  Fallopian tube cancer
Drug target
Afatinib (DG00717): D09724 D09733<JP/US>
Canertinib dihydrochloride: D03350
Dacomitinib (DG01793): D09883 D10514<JP/US>
Lapatinib (DG00715): D04024<JP/US> D08108
Lapuleucel-T: D06610
Margetuximab: D10446<US>
Mubritinib: D04025
Nelipepimut-S: D10344
Neratinib (DG02303): D08950 D10898<US>
Pertuzumab: D05446<JP/US>
Poziotinib (DG03196): D12229 D12230
Runimotamab: D12236
Tesevatinib (DG03101): D11772 D11773
Trastuzumab: D03257<JP/US>
Trastuzumab deruxtecan: D11529<JP/US>
Trastuzumab duocarmazine: D11375
Trastuzumab emtansine: D09980<JP/US>
Tucatinib: D11141<US>
Varlitinib (DG01357): D09689 D09690
Zanidatamab: D12011
Zenocutuzumab: D11991
Brite
KEGG Orthology (KO) [BR:hsa00001]
 09130 Environmental Information Processing
  09132 Signal transduction
   04010 MAPK signaling pathway
    2064 (ERBB2)
   04012 ErbB signaling pathway
    2064 (ERBB2)
   04066 HIF-1 signaling pathway
    2064 (ERBB2)
   04020 Calcium signaling pathway
    2064 (ERBB2)
   04151 PI3K-Akt signaling pathway
    2064 (ERBB2)
 09140 Cellular Processes
  09144 Cellular community - eukaryotes
   04510 Focal adhesion
    2064 (ERBB2)
   04520 Adherens junction
    2064 (ERBB2)
   04530 Tight junction
    2064 (ERBB2)
 09160 Human Diseases
  09161 Cancer: overview
   05200 Pathways in cancer
    2064 (ERBB2)
   05206 MicroRNAs in cancer
    2064 (ERBB2)
   05205 Proteoglycans in cancer
    2064 (ERBB2)
   05230 Central carbon metabolism in cancer
    2064 (ERBB2)
  09162 Cancer: specific types
   05212 Pancreatic cancer
    2064 (ERBB2)
   05226 Gastric cancer
    2064 (ERBB2)
   05219 Bladder cancer
    2064 (ERBB2)
   05215 Prostate cancer
    2064 (ERBB2)
   05213 Endometrial cancer
    2064 (ERBB2)
   05224 Breast cancer
    2064 (ERBB2)
   05223 Non-small cell lung cancer
    2064 (ERBB2)
  09176 Drug resistance: antineoplastic
   01521 EGFR tyrosine kinase inhibitor resistance
    2064 (ERBB2)
   01524 Platinum drug resistance
    2064 (ERBB2)
   01522 Endocrine resistance
    2064 (ERBB2)
 09180 Brite Hierarchies
  09181 Protein families: metabolism
   01001 Protein kinases [BR:hsa01001]
    2064 (ERBB2)
  09183 Protein families: signaling and cellular processes
   04147 Exosome [BR:hsa04147]
    2064 (ERBB2)
   04090 CD molecules [BR:hsa04090]
    2064 (ERBB2)
Enzymes [BR:hsa01000]
 2. Transferases
  2.7  Transferring phosphorus-containing groups
   2.7.10  Protein-tyrosine kinases
    2.7.10.1  receptor protein-tyrosine kinase
     2064 (ERBB2)
Protein kinases [BR:hsa01001]
 Receptor tyrosine kinases (RTK)
  EGFR family [OT]
   2064 (ERBB2)
Exosome [BR:hsa04147]
 Exosomal proteins
  Exosomal proteins of breast cancer cells
   2064 (ERBB2)
CD molecules [BR:hsa04090]
 Proteins
  2064 (ERBB2)
SSDB
Motif
Pfam: PK_Tyr_Ser-Thr Recep_L_domain GF_recep_IV Pkinase Furin-like APH Haspin_kinase Kinase-like
Other DBs
NCBI-GeneID: 2064
NCBI-ProteinID: NP_004439
OMIM: 164870
HGNC: 3430
Ensembl: ENSG00000141736
Pharos: P04626(Tclin)
UniProt: P04626 X5DNK3
Structure
LinkDB
Position
17:39688094..39728658
AA seq 1255 aa
MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNL
ELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNG
DPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLA
LTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQC
AAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACP
YNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSAN
IQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLP
DLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTV
PWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQEC
VEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARC
PSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVG
ILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETEL
RKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSP
YVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVR
LVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFT
HQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWM
IDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDA
EEYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEG
AGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYV
NQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQ
GGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV
NT seq 3768 nt   +upstreamnt  +downstreamnt
atggagctggcggccttgtgccgctgggggctcctcctcgccctcttgccccccggagcc
gcgagcacccaagtgtgcaccggcacagacatgaagctgcggctccctgccagtcccgag
acccacctggacatgctccgccacctctaccagggctgccaggtggtgcagggaaacctg
gaactcacctacctgcccaccaatgccagcctgtccttcctgcaggatatccaggaggtg
cagggctacgtgctcatcgctcacaaccaagtgaggcaggtcccactgcagaggctgcgg
attgtgcgaggcacccagctctttgaggacaactatgccctggccgtgctagacaatgga
gacccgctgaacaataccacccctgtcacaggggcctccccaggaggcctgcgggagctg
cagcttcgaagcctcacagagatcttgaaaggaggggtcttgatccagcggaacccccag
ctctgctaccaggacacgattttgtggaaggacatcttccacaagaacaaccagctggct
ctcacactgatagacaccaaccgctctcgggcctgccacccctgttctccgatgtgtaag
ggctcccgctgctggggagagagttctgaggattgtcagagcctgacgcgcactgtctgt
gccggtggctgtgcccgctgcaaggggccactgcccactgactgctgccatgagcagtgt
gctgccggctgcacgggccccaagcactctgactgcctggcctgcctccacttcaaccac
agtggcatctgtgagctgcactgcccagccctggtcacctacaacacagacacgtttgag
tccatgcccaatcccgagggccggtatacattcggcgccagctgtgtgactgcctgtccc
tacaactacctttctacggacgtgggatcctgcaccctcgtctgccccctgcacaaccaa
gaggtgacagcagaggatggaacacagcggtgtgagaagtgcagcaagccctgtgcccga
gtgtgctatggtctgggcatggagcacttgcgagaggtgagggcagttaccagtgccaat
atccaggagtttgctggctgcaagaagatctttgggagcctggcatttctgccggagagc
tttgatggggacccagcctccaacactgccccgctccagccagagcagctccaagtgttt
gagactctggaagagatcacaggttacctatacatctcagcatggccggacagcctgcct
gacctcagcgtcttccagaacctgcaagtaatccggggacgaattctgcacaatggcgcc
tactcgctgaccctgcaagggctgggcatcagctggctggggctgcgctcactgagggaa
ctgggcagtggactggccctcatccaccataacacccacctctgcttcgtgcacacggtg
ccctgggaccagctctttcggaacccgcaccaagctctgctccacactgccaaccggcca
gaggacgagtgtgtgggcgagggcctggcctgccaccagctgtgcgcccgagggcactgc
tggggtccagggcccacccagtgtgtcaactgcagccagttccttcggggccaggagtgc
gtggaggaatgccgagtactgcaggggctccccagggagtatgtgaatgccaggcactgt
ttgccgtgccaccctgagtgtcagccccagaatggctcagtgacctgttttggaccggag
gctgaccagtgtgtggcctgtgcccactataaggaccctcccttctgcgtggcccgctgc
cccagcggtgtgaaacctgacctctcctacatgcccatctggaagtttccagatgaggag
ggcgcatgccagccttgccccatcaactgcacccactcctgtgtggacctggatgacaag
ggctgccccgccgagcagagagccagccctctgacgtccatcatctctgcggtggttggc
attctgctggtcgtggtcttgggggtggtctttgggatcctcatcaagcgacggcagcag
aagatccggaagtacacgatgcggagactgctgcaggaaacggagctggtggagccgctg
acacctagcggagcgatgcccaaccaggcgcagatgcggatcctgaaagagacggagctg
aggaaggtgaaggtgcttggatctggcgcttttggcacagtctacaagggcatctggatc
cctgatggggagaatgtgaaaattccagtggccatcaaagtgttgagggaaaacacatcc
cccaaagccaacaaagaaatcttagacgaagcatacgtgatggctggtgtgggctcccca
tatgtctcccgccttctgggcatctgcctgacatccacggtgcagctggtgacacagctt
atgccctatggctgcctcttagaccatgtccgggaaaaccgcggacgcctgggctcccag
gacctgctgaactggtgtatgcagattgccaaggggatgagctacctggaggatgtgcgg
ctcgtacacagggacttggccgctcggaacgtgctggtcaagagtcccaaccatgtcaaa
attacagacttcgggctggctcggctgctggacattgacgagacagagtaccatgcagat
gggggcaaggtgcccatcaagtggatggcgctggagtccattctccgccggcggttcacc
caccagagtgatgtgtggagttatggtgtgactgtgtgggagctgatgacttttggggcc
aaaccttacgatgggatcccagcccgggagatccctgacctgctggaaaagggggagcgg
ctgccccagccccccatctgcaccattgatgtctacatgatcatggtcaaatgttggatg
attgactctgaatgtcggccaagattccgggagttggtgtctgaattctcccgcatggcc
agggacccccagcgctttgtggtcatccagaatgaggacttgggcccagccagtcccttg
gacagcaccttctaccgctcactgctggaggacgatgacatgggggacctggtggatgct
gaggagtatctggtaccccagcagggcttcttctgtccagaccctgccccgggcgctggg
ggcatggtccaccacaggcaccgcagctcatctaccaggagtggcggtggggacctgaca
ctagggctggagccctctgaagaggaggcccccaggtctccactggcaccctccgaaggg
gctggctccgatgtatttgatggtgacctgggaatgggggcagccaaggggctgcaaagc
ctccccacacatgaccccagccctctacagcggtacagtgaggaccccacagtacccctg
ccctctgagactgatggctacgttgcccccctgacctgcagcccccagcctgaatatgtg
aaccagccagatgttcggccccagcccccttcgccccgagagggccctctgcctgctgcc
cgacctgctggtgccactctggaaaggcccaagactctctccccagggaagaatggggtc
gtcaaagacgtttttgcctttgggggtgccgtggagaaccccgagtacttgacaccccag
ggaggagctgcccctcagccccaccctcctcctgccttcagcccagccttcgacaacctc
tattactgggaccaggacccaccagagcggggggctccacccagcaccttcaaagggaca
cctacggcagagaacccagagtacctgggtctggacgtgccagtgtga

KEGG   Homo sapiens (human): 2321
Entry
2321              CDS       T01001                                 
Symbol
FLT1, FLT, FLT-1, VEGFR-1, VEGFR1
Name
(RefSeq) fms related receptor tyrosine kinase 1
  KO
K05096  FMS-like tyrosine kinase 1 [EC:2.7.10.1]
Organism
hsa  Homo sapiens (human)
Pathway
hsa04010  MAPK signaling pathway
hsa04014  Ras signaling pathway
hsa04015  Rap1 signaling pathway
hsa04020  Calcium signaling pathway
hsa04066  HIF-1 signaling pathway
hsa04151  PI3K-Akt signaling pathway
hsa04510  Focal adhesion
hsa05202  Transcriptional misregulation in cancer
hsa05323  Rheumatoid arthritis
Network
nt06240  Transcription
  Element
N00141  PAX3-FOXO1 fusion to transcriptional activation
Drug target
Axitinib: D03218<JP/US>
Cediranib (DG01360): D08881 D08883
Dovitinib lactate: D08907
Fruquintinib: D11977
Icrucumab: D09926
Ilorasertib: D10423
Lenvatinib (DG01362): D09919 D09920<JP/US>
Linifanib: D09635
Lucitanib: D11762
Motesanib (DG01262): D06678 D08947
Nintedanib (DG01374): D10396<JP/US> D10481
Pazopanib: D05380<JP/US>
Regorafenib (DG00720): D10137<JP/US> D10138
Selpercatinib: D11713<JP/US>
Sitravatinib (DG03045): D11140 D11541
Sunitinib (DG00712): D06402<JP/US> D08552
Surufatinib: D11885
Tivozanib (DG01375): D09683 D10190<US>
Vatalanib: D06285
Brite
KEGG Orthology (KO) [BR:hsa00001]
 09130 Environmental Information Processing
  09132 Signal transduction
   04010 MAPK signaling pathway
    2321 (FLT1)
   04014 Ras signaling pathway
    2321 (FLT1)
   04015 Rap1 signaling pathway
    2321 (FLT1)
   04066 HIF-1 signaling pathway
    2321 (FLT1)
   04020 Calcium signaling pathway
    2321 (FLT1)
   04151 PI3K-Akt signaling pathway
    2321 (FLT1)
 09140 Cellular Processes
  09144 Cellular community - eukaryotes
   04510 Focal adhesion
    2321 (FLT1)
 09160 Human Diseases
  09161 Cancer: overview
   05202 Transcriptional misregulation in cancer
    2321 (FLT1)
  09163 Immune disease
   05323 Rheumatoid arthritis
    2321 (FLT1)
 09180 Brite Hierarchies
  09181 Protein families: metabolism
   01001 Protein kinases [BR:hsa01001]
    2321 (FLT1)
Enzymes [BR:hsa01000]
 2. Transferases
  2.7  Transferring phosphorus-containing groups
   2.7.10  Protein-tyrosine kinases
    2.7.10.1  receptor protein-tyrosine kinase
     2321 (FLT1)
Protein kinases [BR:hsa01001]
 Receptor tyrosine kinases (RTK)
  VEGFR family [OT]
   2321 (FLT1)
SSDB
Motif
Pfam: PK_Tyr_Ser-Thr Ig_3 I-set Pkinase ig Ig_2 V-set VEGFR-2_TMD Ig_4 C1-set Ig_6 Ig_5 Marek_A Herpes_gE Haspin_kinase Adeno_E3_CR1
Other DBs
NCBI-GeneID: 2321
NCBI-ProteinID: NP_002010
OMIM: 165070
HGNC: 3763
Ensembl: ENSG00000102755
Pharos: P17948(Tclin)
UniProt: P17948 L7RSL3
Structure
LinkDB
Position
13:complement(28300346..28495128)
AA seq 1338 aa
MVSYWDTGVLLCALLSCLLLTGSSSGSKLKDPELSLKGTQHIMQAGQTLHLQCRGEAAHK
WSLPEMVSKESERLSITKSACGRNGKQFCSTLTLNTAQANHTGFYSCKYLAVPTSKKKET
ESAIYIFISDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPD
GKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVQISTPRPV
KLLRGHTLVLNCTATTPLNTRVQMTWSYPDEKNKRASVRRRIDQSNSHANIFYSVLTIDK
MQNKDKGLYTCRVRSGPSFKSVNTSVHIYDKAFITVKHRKQQVLETVAGKRSYRLSMKVK
AFPSPEVVWLKDGLPATEKSARYLTRGYSLIIKDVTEEDAGNYTILLSIKQSNVFKNLTA
TLIVNVKPQIYEKAVSSFPDPALYPLGSRQILTCTAYGIPQPTIKWFWHPCNHNHSEARC
DFCSNNEESFILDADSNMGNRIESITQRMAIIEGKNKMASTLVVADSRISGIYICIASNK
VGTVGRNISFYITDVPNGFHVNLEKMPTEGEDLKLSCTVNKFLYRDVTWILLRTVNNRTM
HYSISKQKMAITKEHSITLNLTIMNVSLQDSGTYACRARNVYTGEEILQKKEITIRDQEA
PYLLRNLSDHTVAISSSTTLDCHANGVPEPQITWFKNNHKIQQEPGIILGPGSSTLFIER
VTEEDEGVYHCKATNQKGSVESSAYLTVQGTSDKSNLELITLTCTCVAATLFWLLLTLFI
RKMKRSSSEIKTDYLSIIMDPDEVPLDEQCERLPYDASKWEFARERLKLGKSLGRGAFGK
VVQASAFGIKKSPTCRTVAVKMLKEGATASEYKALMTELKILTHIGHHLNVVNLLGACTK
QGGPLMVIVEYCKYGNLSNYLKSKRDLFFLNKDAALHMEPKKEKMEPGLEQGKKPRLDSV
TSSESFASSGFQEDKSLSDVEEEEDSDGFYKEPITMEDLISYSFQVARGMEFLSSRKCIH
RDLAARNILLSENNVVKICDFGLARDIYKNPDYVRKGDTRLPLKWMAPESIFDKIYSTKS
DVWSYGVLLWEIFSLGGSPYPGVQMDEDFCSRLREGMRMRAPEYSTPEIYQIMLDCWHRD
PKERPRFAELVEKLGDLLQANVQQDGKDYIPINAILTGNSGFTYSTPAFSEDFFKESISA
PKFNSGSSDDVRYVNAFKFMSLERIKTFEELLPNATSMFDDYQGDSSTLLASPMLKRFTW
TDSKPKASLKIDLRVTSKSKESGLSDVSRPSFCHSSCGHVSEGKRRFTYDHAELERKIAC
CSPPPDYNSVVLYSTPPI
NT seq 4017 nt   +upstreamnt  +downstreamnt
atggtcagctactgggacaccggggtcctgctgtgcgcgctgctcagctgtctgcttctc
acaggatctagttcaggttcaaaattaaaagatcctgaactgagtttaaaaggcacccag
cacatcatgcaagcaggccagacactgcatctccaatgcaggggggaagcagcccataaa
tggtctttgcctgaaatggtgagtaaggaaagcgaaaggctgagcataactaaatctgcc
tgtggaagaaatggcaaacaattctgcagtactttaaccttgaacacagctcaagcaaac
cacactggcttctacagctgcaaatatctagctgtacctacttcaaagaagaaggaaaca
gaatctgcaatctatatatttattagtgatacaggtagacctttcgtagagatgtacagt
gaaatccccgaaattatacacatgactgaaggaagggagctcgtcattccctgccgggtt
acgtcacctaacatcactgttactttaaaaaagtttccacttgacactttgatccctgat
ggaaaacgcataatctgggacagtagaaagggcttcatcatatcaaatgcaacgtacaaa
gaaatagggcttctgacctgtgaagcaacagtcaatgggcatttgtataagacaaactat
ctcacacatcgacaaaccaatacaatcatagatgtccaaataagcacaccacgcccagtc
aaattacttagaggccatactcttgtcctcaattgtactgctaccactcccttgaacacg
agagttcaaatgacctggagttaccctgatgaaaaaaataagagagcttccgtaaggcga
cgaattgaccaaagcaattcccatgccaacatattctacagtgttcttactattgacaaa
atgcagaacaaagacaaaggactttatacttgtcgtgtaaggagtggaccatcattcaaa
tctgttaacacctcagtgcatatatatgataaagcattcatcactgtgaaacatcgaaaa
cagcaggtgcttgaaaccgtagctggcaagcggtcttaccggctctctatgaaagtgaag
gcatttccctcgccggaagttgtatggttaaaagatgggttacctgcgactgagaaatct
gctcgctatttgactcgtggctactcgttaattatcaaggacgtaactgaagaggatgca
gggaattatacaatcttgctgagcataaaacagtcaaatgtgtttaaaaacctcactgcc
actctaattgtcaatgtgaaaccccagatttacgaaaaggccgtgtcatcgtttccagac
ccggctctctacccactgggcagcagacaaatcctgacttgtaccgcatatggtatccct
caacctacaatcaagtggttctggcacccctgtaaccataatcattccgaagcaaggtgt
gacttttgttccaataatgaagagtcctttatcctggatgctgacagcaacatgggaaac
agaattgagagcatcactcagcgcatggcaataatagaaggaaagaataagatggctagc
accttggttgtggctgactctagaatttctggaatctacatttgcatagcttccaataaa
gttgggactgtgggaagaaacataagcttttatatcacagatgtgccaaatgggtttcat
gttaacttggaaaaaatgccgacggaaggagaggacctgaaactgtcttgcacagttaac
aagttcttatacagagacgttacttggattttactgcggacagttaataacagaacaatg
cactacagtattagcaagcaaaaaatggccatcactaaggagcactccatcactcttaat
cttaccatcatgaatgtttccctgcaagattcaggcacctatgcctgcagagccaggaat
gtatacacaggggaagaaatcctccagaagaaagaaattacaatcagagatcaggaagca
ccatacctcctgcgaaacctcagtgatcacacagtggccatcagcagttccaccacttta
gactgtcatgctaatggtgtccccgagcctcagatcacttggtttaaaaacaaccacaaa
atacaacaagagcctggaattattttaggaccaggaagcagcacgctgtttattgaaaga
gtcacagaagaggatgaaggtgtctatcactgcaaagccaccaaccagaagggctctgtg
gaaagttcagcatacctcactgttcaaggaacctcggacaagtctaatctggagctgatc
actctaacatgcacctgtgtggctgcgactctcttctggctcctattaaccctctttatc
cgaaaaatgaaaaggtcttcttctgaaataaagactgactacctatcaattataatggac
ccagatgaagttcctttggatgagcagtgtgagcggctcccttatgatgccagcaagtgg
gagtttgcccgggagagacttaaactgggcaaatcacttggaagaggggcttttggaaaa
gtggttcaagcatcagcatttggcattaagaaatcacctacgtgccggactgtggctgtg
aaaatgctgaaagagggggccacggccagcgagtacaaagctctgatgactgagctaaaa
atcttgacccacattggccaccatctgaacgtggttaacctgctgggagcctgcaccaag
caaggagggcctctgatggtgattgttgaatactgcaaatatggaaatctctccaactac
ctcaagagcaaacgtgacttattttttctcaacaaggatgcagcactacacatggagcct
aagaaagaaaaaatggagccaggcctggaacaaggcaagaaaccaagactagatagcgtc
accagcagcgaaagctttgcgagctccggctttcaggaagataaaagtctgagtgatgtt
gaggaagaggaggattctgacggtttctacaaggagcccatcactatggaagatctgatt
tcttacagttttcaagtggccagaggcatggagttcctgtcttccagaaagtgcattcat
cgggacctggcagcgagaaacattcttttatctgagaacaacgtggtgaagatttgtgat
tttggccttgcccgggatatttataagaaccccgattatgtgagaaaaggagatactcga
cttcctctgaaatggatggctcctgaatctatctttgacaaaatctacagcaccaagagc
gacgtgtggtcttacggagtattgctgtgggaaatcttctccttaggtgggtctccatac
ccaggagtacaaatggatgaggacttttgcagtcgcctgagggaaggcatgaggatgaga
gctcctgagtactctactcctgaaatctatcagatcatgctggactgctggcacagagac
ccaaaagaaaggccaagatttgcagaacttgtggaaaaactaggtgatttgcttcaagca
aatgtacaacaggatggtaaagactacatcccaatcaatgccatactgacaggaaatagt
gggtttacatactcaactcctgccttctctgaggacttcttcaaggaaagtatttcagct
ccgaagtttaattcaggaagctctgatgatgtcagatacgtaaatgctttcaagttcatg
agcctggaaagaatcaaaacctttgaagaacttttaccgaatgccacctccatgtttgat
gactaccagggcgacagcagcactctgttggcctctcccatgctgaagcgcttcacctgg
actgacagcaaacccaaggcctcgctcaagattgacttgagagtaaccagtaaaagtaag
gagtcggggctgtctgatgtcagcaggcccagtttctgccattccagctgtgggcacgtc
agcgaaggcaagcgcaggttcacctacgaccacgctgagctggaaaggaaaatcgcgtgc
tgctccccgcccccagactacaactcggtggtcctgtactccaccccacccatctag

KEGG   Homo sapiens (human): 2324
Entry
2324              CDS       T01001                                 
Symbol
FLT4, CHTD7, FLT-4, FLT41, LMPH1A, LMPHM1, PCL, VEGFR-3, VEGFR3
Name
(RefSeq) fms related receptor tyrosine kinase 4
  KO
K05097  FMS-like tyrosine kinase 4 [EC:2.7.10.1]
Organism
hsa  Homo sapiens (human)
Pathway
hsa04010  MAPK signaling pathway
hsa04014  Ras signaling pathway
hsa04015  Rap1 signaling pathway
hsa04020  Calcium signaling pathway
hsa04151  PI3K-Akt signaling pathway
hsa04510  Focal adhesion
hsa05200  Pathways in cancer
hsa05224  Breast cancer
Network
nt06216  NOTCH signaling
nt06270  Breast cancer
  Element
N00087  NOTCH-overexpression to Notch signaling pathway
Disease
H00535  Lymphatic malformation
H01471  Lymphangioma
H02199  Congenital heart defects, multiple type
Drug target
Axitinib: D03218<JP/US>
Cediranib (DG01360): D08881 D08883
Dovitinib lactate: D08907
Fruquintinib: D11977
Lenvatinib (DG01362): D09919 D09920<JP/US>
Linifanib: D09635
Lucitanib: D11762
Motesanib (DG01262): D06678 D08947
Nintedanib (DG01374): D10396<JP/US> D10481
Pazopanib: D05380<JP/US>
Regorafenib (DG00720): D10137<JP/US> D10138
Selpercatinib: D11713<JP/US>
Sitravatinib (DG03045): D11140 D11541
Sorafenib (DG00713): D06272<JP/US> D08524
Sunitinib (DG00712): D06402<JP/US> D08552
Surufatinib: D11885
Tesevatinib (DG03101): D11772 D11773
Tivozanib (DG01375): D09683 D10190<US>
Vatalanib: D06285
Brite
KEGG Orthology (KO) [BR:hsa00001]
 09130 Environmental Information Processing
  09132 Signal transduction
   04010 MAPK signaling pathway
    2324 (FLT4)
   04014 Ras signaling pathway
    2324 (FLT4)
   04015 Rap1 signaling pathway
    2324 (FLT4)
   04020 Calcium signaling pathway
    2324 (FLT4)
   04151 PI3K-Akt signaling pathway
    2324 (FLT4)
 09140 Cellular Processes
  09144 Cellular community - eukaryotes
   04510 Focal adhesion
    2324 (FLT4)
 09160 Human Diseases
  09161 Cancer: overview
   05200 Pathways in cancer
    2324 (FLT4)
  09162 Cancer: specific types
   05224 Breast cancer
    2324 (FLT4)
 09180 Brite Hierarchies
  09181 Protein families: metabolism
   01001 Protein kinases [BR:hsa01001]
    2324 (FLT4)
Enzymes [BR:hsa01000]
 2. Transferases
  2.7  Transferring phosphorus-containing groups
   2.7.10  Protein-tyrosine kinases
    2.7.10.1  receptor protein-tyrosine kinase
     2324 (FLT4)
Protein kinases [BR:hsa01001]
 Receptor tyrosine kinases (RTK)
  VEGFR family [OT]
   2324 (FLT4)
SSDB
Motif
Pfam: PK_Tyr_Ser-Thr Ig_3 Ig_2 I-set Pkinase ig VEGFR-2_TMD V-set C1-set Haspin_kinase
Other DBs
NCBI-GeneID: 2324
NCBI-ProteinID: NP_891555
OMIM: 136352
HGNC: 3767
Ensembl: ENSG00000037280
Pharos: P35916(Tclin)
UniProt: P35916
Structure
LinkDB
Position
5:complement(180601506..180650298)
AA seq 1363 aa
MQRGAALCLRLWLCLGLLDGLVSGYSMTPPTLNITEESHVIDTGDSLSISCRGQHPLEWA
WPGAQEAPATGDKDSEDTGVVRDCEGTDARPYCKVLLLHEVHANDTGSYVCYYKYIKARI
EGTTAASSYVFVRDFEQPFINKPDTLLVNRKDAMWVPCLVSIPGLNVTLRSQSSVLWPDG
QEVVWDDRRGMLVSTPLLHDALYLQCETTWGDQDFLSNPFLVHITGNELYDIQLLPRKSL
ELLVGEKLVLNCTVWAEFNSGVTFDWDYPGKQAERGKWVPERRSQQTHTELSSILTIHNV
SQHDLGSYVCKANNGIQRFRESTEVIVHENPFISVEWLKGPILEATAGDELVKLPVKLAA
YPPPEFQWYKDGKALSGRHSPHALVLKEVTEASTGTYTLALWNSAAGLRRNISLELVVNV
PPQIHEKEASSPSIYSRHSRQALTCTAYGVPLPLSIQWHWRPWTPCKMFAQRSLRRRQQQ
DLMPQCRDWRAVTTQDAVNPIESLDTWTEFVEGKNKTVSKLVIQNANVSAMYKCVVSNKV
GQDERLIYFYVTTIPDGFTIESKPSEELLEGQPVLLSCQADSYKYEHLRWYRLNLSTLHD
AHGNPLLLDCKNVHLFATPLAASLEEVAPGARHATLSLSIPRVAPEHEGHYVCEVQDRRS
HDKHCHKKYLSVQALEAPRLTQNLTDLLVNVSDSLEMQCLVAGAHAPSIVWYKDERLLEE
KSGVDLADSNQKLSIQRVREEDAGRYLCSVCNAKGCVNSSASVAVEGSEDKGSMEIVILV
GTGVIAVFFWVLLLLIFCNMRRPAHADIKTGYLSIIMDPGEVPLEEQCEYLSYDASQWEF
PRERLHLGRVLGYGAFGKVVEASAFGIHKGSSCDTVAVKMLKEGATASEHRALMSELKIL
IHIGNHLNVVNLLGACTKPQGPLMVIVEFCKYGNLSNFLRAKRDAFSPCAEKSPEQRGRF
RAMVELARLDRRRPGSSDRVLFARFSKTEGGARRASPDQEAEDLWLSPLTMEDLVCYSFQ
VARGMEFLASRKCIHRDLAARNILLSESDVVKICDFGLARDIYKDPDYVRKGSARLPLKW
MAPESIFDKVYTTQSDVWSFGVLLWEIFSLGASPYPGVQINEEFCQRLRDGTRMRAPELA
TPAIRRIMLNCWSGDPKARPAFSELVEILGDLLQGRGLQEEEEVCMAPRSSQSSEEGSFS
QVSTMALHIAQADAEDSPPSLQRHSLAARYYNWVSFPGCLARGAETRGSSRMKTFEEFPM
TPTTYKGSVDNQTDSGMVLASEEFEQIESRHRQESGFSCKGPGQNVAVTRAHPDSQGRRR
RPERGARGGQVFYNSEYGELSEPSEEDHCSPSARVTFFTDNSY
NT seq 4092 nt   +upstreamnt  +downstreamnt
atgcagcggggcgccgcgctgtgcctgcgactgtggctctgcctgggactcctggacggc
ctggtgagtggctactccatgacccccccgaccttgaacatcacggaggagtcacacgtc
atcgacaccggtgacagcctgtccatctcctgcaggggacagcaccccctcgagtgggct
tggccaggagctcaggaggcgccagccaccggagacaaggacagcgaggacacgggggtg
gtgcgagactgcgagggcacagacgccaggccctactgcaaggtgttgctgctgcacgag
gtacatgccaacgacacaggcagctacgtctgctactacaagtacatcaaggcacgcatc
gagggcaccacggccgccagctcctacgtgttcgtgagagactttgagcagccattcatc
aacaagcctgacacgctcttggtcaacaggaaggacgccatgtgggtgccctgtctggtg
tccatccccggcctcaatgtcacgctgcgctcgcaaagctcggtgctgtggccagacggg
caggaggtggtgtgggatgaccggcggggcatgctcgtgtccacgccactgctgcacgat
gccctgtacctgcagtgcgagaccacctggggagaccaggacttcctttccaaccccttc
ctggtgcacatcacaggcaacgagctctatgacatccagctgttgcccaggaagtcgctg
gagctgctggtaggggagaagctggtcctgaactgcaccgtgtgggctgagtttaactca
ggtgtcacctttgactgggactacccagggaagcaggcagagcggggtaagtgggtgccc
gagcgacgctcccagcagacccacacagaactctccagcatcctgaccatccacaacgtc
agccagcacgacctgggctcgtatgtgtgcaaggccaacaacggcatccagcgatttcgg
gagagcaccgaggtcattgtgcatgaaaatcccttcatcagcgtcgagtggctcaaagga
cccatcctggaggccacggcaggagacgagctggtgaagctgcccgtgaagctggcagcg
taccccccgcccgagttccagtggtacaaggatggaaaggcactgtccgggcgccacagt
ccacatgccctggtgctcaaggaggtgacagaggccagcacaggcacctacaccctcgcc
ctgtggaactccgctgctggcctgaggcgcaacatcagcctggagctggtggtgaatgtg
cccccccagatacatgagaaggaggcctcctcccccagcatctactcgcgtcacagccgc
caggccctcacctgcacggcctacggggtgcccctgcctctcagcatccagtggcactgg
cggccctggacaccctgcaagatgtttgcccagcgtagtctccggcggcggcagcagcaa
gacctcatgccacagtgccgtgactggagggcggtgaccacgcaggatgccgtgaacccc
atcgagagcctggacacctggaccgagtttgtggagggaaagaataagactgtgagcaag
ctggtgatccagaatgccaacgtgtctgccatgtacaagtgtgtggtctccaacaaggtg
ggccaggatgagcggctcatctacttctatgtgaccaccatccccgacggcttcaccatc
gaatccaagccatccgaggagctactagagggccagccggtgctcctgagctgccaagcc
gacagctacaagtacgagcatctgcgctggtaccgcctcaacctgtccacgctgcacgat
gcgcacgggaacccgcttctgctcgactgcaagaacgtgcatctgttcgccacccctctg
gccgccagcctggaggaggtggcacctggggcgcgccacgccacgctcagcctgagtatc
ccccgcgtcgcgcccgagcacgagggccactatgtgtgcgaagtgcaagaccggcgcagc
catgacaagcactgccacaagaagtacctgtcggtgcaggccctggaagcccctcggctc
acgcagaacttgaccgacctcctggtgaacgtgagcgactcgctggagatgcagtgcttg
gtggccggagcgcacgcgcccagcatcgtgtggtacaaagacgagaggctgctggaggaa
aagtctggagtcgacttggcggactccaaccagaagctgagcatccagcgcgtgcgcgag
gaggatgcgggacgctatctgtgcagcgtgtgcaacgccaagggctgcgtcaactcctcc
gccagcgtggccgtggaaggctccgaggataagggcagcatggagatcgtgatccttgtc
ggtaccggcgtcatcgctgtcttcttctgggtcctcctcctcctcatcttctgtaacatg
aggaggccggcccacgcagacatcaagacgggctacctgtccatcatcatggaccccggg
gaggtgcctctggaggagcaatgcgaatacctgtcctacgatgccagccagtgggaattc
ccccgagagcggctgcacctggggagagtgctcggctacggcgccttcgggaaggtggtg
gaagcctccgctttcggcatccacaagggcagcagctgtgacaccgtggccgtgaaaatg
ctgaaagagggcgccacggccagcgagcaccgcgcgctgatgtcggagctcaagatcctc
attcacatcggcaaccacctcaacgtggtcaacctcctcggggcgtgcaccaagccgcag
ggccccctcatggtgatcgtggagttctgcaagtacggcaacctctccaacttcctgcgc
gccaagcgggacgccttcagcccctgcgcggagaagtctcccgagcagcgcggacgcttc
cgcgccatggtggagctcgccaggctggatcggaggcggccggggagcagcgacagggtc
ctcttcgcgcggttctcgaagaccgagggcggagcgaggcgggcttctccagaccaagaa
gctgaggacctgtggctgagcccgctgaccatggaagatcttgtctgctacagcttccag
gtggccagagggatggagttcctggcttcccgaaagtgcatccacagagacctggctgct
cggaacattctgctgtcggaaagcgacgtggtgaagatctgtgactttggccttgcccgg
gacatctacaaagaccccgactacgtccgcaagggcagtgcccggctgcccctgaagtgg
atggcccctgaaagcatcttcgacaaggtgtacaccacgcagagtgacgtgtggtccttt
ggggtgcttctctgggagatcttctctctgggggcctccccgtaccctggggtgcagatc
aatgaggagttctgccagcggctgagagacggcacaaggatgagggccccggagctggcc
actcccgccatacgccgcatcatgctgaactgctggtccggagaccccaaggcgagacct
gcattctcggagctggtggagatcctgggggacctgctccagggcaggggcctgcaagag
gaagaggaggtctgcatggccccgcgcagctctcagagctcagaagagggcagcttctcg
caggtgtccaccatggccctacacatcgcccaggctgacgctgaggacagcccgccaagc
ctgcagcgccacagcctggccgccaggtattacaactgggtgtcctttcccgggtgcctg
gccagaggggctgagacccgtggttcctccaggatgaagacatttgaggaattccccatg
accccaacgacctacaaaggctctgtggacaaccagacagacagtgggatggtgctggcc
tcggaggagtttgagcagatagagagcaggcatagacaagaaagcggcttcagctgtaaa
ggacctggccagaatgtggctgtgaccagggcacaccctgactcccaagggaggcggcgg
cggcctgagcggggggcccgaggaggccaggtgttttacaacagcgagtatggggagctg
tcggagccaagcgaggaggaccactgctccccgtctgcccgcgtgactttcttcacagac
aacagctactaa

KEGG   Homo sapiens (human): 3480
Entry
3480              CDS       T01001                                 
Symbol
IGF1R, CD221, IGFIR, IGFR, JTK13
Name
(RefSeq) insulin like growth factor 1 receptor
  KO
K05087  insulin-like growth factor 1 receptor [EC:2.7.10.1]
Organism
hsa  Homo sapiens (human)
Pathway
hsa01521  EGFR tyrosine kinase inhibitor resistance
hsa01522  Endocrine resistance
hsa04010  MAPK signaling pathway
hsa04014  Ras signaling pathway
hsa04015  Rap1 signaling pathway
hsa04066  HIF-1 signaling pathway
hsa04068  FoxO signaling pathway
hsa04114  Oocyte meiosis
hsa04140  Autophagy - animal
hsa04144  Endocytosis
hsa04150  mTOR signaling pathway
hsa04151  PI3K-Akt signaling pathway
hsa04152  AMPK signaling pathway
hsa04211  Longevity regulating pathway
hsa04213  Longevity regulating pathway - multiple species
hsa04510  Focal adhesion
hsa04520  Adherens junction
hsa04550  Signaling pathways regulating pluripotency of stem cells
hsa04730  Long-term depression
hsa04913  Ovarian steroidogenesis
hsa04914  Progesterone-mediated oocyte maturation
hsa05200  Pathways in cancer
hsa05202  Transcriptional misregulation in cancer
hsa05205  Proteoglycans in cancer
hsa05214  Glioma
hsa05215  Prostate cancer
hsa05218  Melanoma
hsa05224  Breast cancer
hsa05225  Hepatocellular carcinoma
Network
nt06114  PI3K signaling (viruses)
nt06164  Kaposi sarcoma-associated herpesvirus (KSHV)
nt06166  Human papillomavirus (HPV)
nt06167  Human cytomegalovirus (HCMV)
nt06168  Herpes simplex virus 1 (HSV-1)
nt06210  ERK signaling
nt06214  PI3K signaling
nt06240  Transcription
nt06263  Hepatocellular carcinoma
nt06324  GHRH-GH-IGF signaling
  Element
N00119  MLL-AF4 fusion to transcriptional activation
N00182  IGF-IGFR-PI3K-NFKB signaling pathway
N00233  IGF-IGF1R-RAS-ERK signaling pathway
N00234  IGF2-IGF1R-PI3K signaling pathway
N00235  IGF2-overexpression to RAS-ERK signaling pathway
N00236  IGF2-overexpression to PI3K signaling pathway
N00237  IGF1R-overexpression to RAS-ERK signaling pathway
N00238  IGF1R-overexpression to PI3K signaling pathway
N00582  IGF-IGF1R-PI3K signaling pathway
N00913  Mutation-inactivated IGF1 to RAS-ERK signaling pathway
N00914  Mutation-inactivated IGF1R to RAS-ERK signaling pathway
Disease
H00015  Malignant pleural mesothelioma
H00048  Hepatocellular carcinoma
H00050  Synovial sarcoma
H01274  Growth delay due to insulin-like growth factor I resistance
Drug target
Cixutumumab: D09328
Dalotuzumab: D09746
Figitumumab: D09345
Ganitumab: D09908
Ibutamoren mesylate: D04491
Istiratumab: D10943
Linsitinib: D09925
Mecasermin: D03297<JP/US>
Mecasermin rinfabate: D04870
Robatumumab: D10056
Teprotumumab: D09680<US>
Toremifene (DG00735): D00967<JP/US> D08620
Brite
KEGG Orthology (KO) [BR:hsa00001]
 09130 Environmental Information Processing
  09132 Signal transduction
   04010 MAPK signaling pathway
    3480 (IGF1R)
   04014 Ras signaling pathway
    3480 (IGF1R)
   04015 Rap1 signaling pathway
    3480 (IGF1R)
   04066 HIF-1 signaling pathway
    3480 (IGF1R)
   04068 FoxO signaling pathway
    3480 (IGF1R)
   04151 PI3K-Akt signaling pathway
    3480 (IGF1R)
   04152 AMPK signaling pathway
    3480 (IGF1R)
   04150 mTOR signaling pathway
    3480 (IGF1R)
 09140 Cellular Processes
  09141 Transport and catabolism
   04144 Endocytosis
    3480 (IGF1R)
   04140 Autophagy - animal
    3480 (IGF1R)
  09143 Cell growth and death
   04114 Oocyte meiosis
    3480 (IGF1R)
  09144 Cellular community - eukaryotes
   04510 Focal adhesion
    3480 (IGF1R)
   04520 Adherens junction
    3480 (IGF1R)
   04550 Signaling pathways regulating pluripotency of stem cells
    3480 (IGF1R)
 09150 Organismal Systems
  09152 Endocrine system
   04913 Ovarian steroidogenesis
    3480 (IGF1R)
   04914 Progesterone-mediated oocyte maturation
    3480 (IGF1R)
  09156 Nervous system
   04730 Long-term depression
    3480 (IGF1R)
  09149 Aging
   04211 Longevity regulating pathway
    3480 (IGF1R)
   04213 Longevity regulating pathway - multiple species
    3480 (IGF1R)
 09160 Human Diseases
  09161 Cancer: overview
   05200 Pathways in cancer
    3480 (IGF1R)
   05202 Transcriptional misregulation in cancer
    3480 (IGF1R)
   05205 Proteoglycans in cancer
    3480 (IGF1R)
  09162 Cancer: specific types
   05225 Hepatocellular carcinoma
    3480 (IGF1R)
   05214 Glioma
    3480 (IGF1R)
   05218 Melanoma
    3480 (IGF1R)
   05215 Prostate cancer
    3480 (IGF1R)
   05224 Breast cancer
    3480 (IGF1R)
  09176 Drug resistance: antineoplastic
   01521 EGFR tyrosine kinase inhibitor resistance
    3480 (IGF1R)
   01522 Endocrine resistance
    3480 (IGF1R)
 09180 Brite Hierarchies
  09181 Protein families: metabolism
   01001 Protein kinases [BR:hsa01001]
    3480 (IGF1R)
  09183 Protein families: signaling and cellular processes
   04090 CD molecules [BR:hsa04090]
    3480 (IGF1R)
Enzymes [BR:hsa01000]
 2. Transferases
  2.7  Transferring phosphorus-containing groups
   2.7.10  Protein-tyrosine kinases
    2.7.10.1  receptor protein-tyrosine kinase
     3480 (IGF1R)
Protein kinases [BR:hsa01001]
 Receptor tyrosine kinases (RTK)
  INSR family [OT]
   3480 (IGF1R)
CD molecules [BR:hsa04090]
 Proteins
  3480 (IGF1R)
SSDB
Motif
Pfam: PK_Tyr_Ser-Thr Recep_L_domain Pkinase Furin-like fn3 Kinase-like DUF4476 Insulin_TMD
Other DBs
NCBI-GeneID: 3480
NCBI-ProteinID: NP_000866
OMIM: 147370
HGNC: 5465
Ensembl: ENSG00000140443
Pharos: P08069(Tclin)
UniProt: P08069
Structure
LinkDB
Position
15:98648539..98964530
AA seq 1367 aa
MKSGSGGGSPTSLWGLLFLSAALSLWPTSGEICGPGIDIRNDYQQLKRLENCTVIEGYLH
ILLISKAEDYRSYRFPKLTVITEYLLLFRVAGLESLGDLFPNLTVIRGWKLFYNYALVIF
EMTNLKDIGLYNLRNITRGAIRIEKNADLCYLSTVDWSLILDAVSNNYIVGNKPPKECGD
LCPGTMEEKPMCEKTTINNEYNYRCWTTNRCQKMCPSTCGKRACTENNECCHPECLGSCS
APDNDTACVACRHYYYAGVCVPACPPNTYRFEGWRCVDRDFCANILSAESSDSEGFVIHD
GECMQECPSGFIRNGSQSMYCIPCEGPCPKVCEEEKKTKTIDSVTSAQMLQGCTIFKGNL
LINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLSFLKNLRLILGEEQLEGNYSF
YVLDNQNLQQLWDWDHRNLTIKAGKMYFAFNPKLCVSEIYRMEEVTGTKGRQSKGDINTR
NNGERASCESDVLHFTSTTTSKNRIIITWHRYRPPDYRDLISFTVYYKEAPFKNVTEYDG
QDACGSNSWNMVDVDLPPNKDVEPGILLHGLKPWTQYAVYVKAVTLTMVENDHIRGAKSE
ILYIRTNASVPSIPLDVLSASNSSSQLIVKWNPPSLPNGNLSYYIVRWQRQPQDGYLYRH
NYCSKDKIPIRKYADGTIDIEEVTENPKTEVCGGEKGPCCACPKTEAEKQAEKEEAEYRK
VFENFLHNSIFVPRPERKRRDVMQVANTTMSSRSRNTTAADTYNITDPEELETEYPFFES
RVDNKERTVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFARTMPAEGADDIPGPVTW
EPRPENSIFLKWPEPENPNGLILMYEIKYGSQVEDQRECVSRQEYRKYGGAKLNRLNPGN
YTARIQATSLSGNGSWTDPVFFYVQAKTGYENFIHLIIALPVAVLLIVGGLVIMLYVFHR
KRNNSRLGNGVLYASVNPEYFSAADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKG
VVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIME
LMTRGDLKSYLRSLRPEMENNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARN
CMVAEDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGV
VLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFL
EIISSIKEEMEPGFREVSFYYSEENKLPEPEELDLEPENMESVPLDPSASSSSLPLPDRH
SGHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALPLPQSSTC
NT seq 4104 nt   +upstreamnt  +downstreamnt
atgaagtctggctccggaggagggtccccgacctcgctgtgggggctcctgtttctctcc
gccgcgctctcgctctggccgacgagtggagaaatctgcgggccaggcatcgacatccgc
aacgactatcagcagctgaagcgcctggagaactgcacggtgatcgagggctacctccac
atcctgctcatctccaaggccgaggactaccgcagctaccgcttccccaagctcacggtc
attaccgagtacttgctgctgttccgagtggctggcctcgagagcctcggagacctcttc
cccaacctcacggtcatccgcggctggaaactcttctacaactacgccctggtcatcttc
gagatgaccaatctcaaggatattgggctttacaacctgaggaacattactcggggggcc
atcaggattgagaaaaatgctgacctctgttacctctccactgtggactggtccctgatc
ctggatgcggtgtccaataactacattgtggggaataagcccccaaaggaatgtggggac
ctgtgtccagggaccatggaggagaagccgatgtgtgagaagaccaccatcaacaatgag
tacaactaccgctgctggaccacaaaccgctgccagaaaatgtgcccaagcacgtgtggg
aagcgggcgtgcaccgagaacaatgagtgctgccaccccgagtgcctgggcagctgcagc
gcgcctgacaacgacacggcctgtgtagcttgccgccactactactatgccggtgtctgt
gtgcctgcctgcccgcccaacacctacaggtttgagggctggcgctgtgtggaccgtgac
ttctgcgccaacatcctcagcgccgagagcagcgactccgaggggtttgtgatccacgac
ggcgagtgcatgcaggagtgcccctcgggcttcatccgcaacggcagccagagcatgtac
tgcatcccttgtgaaggtccttgcccgaaggtctgtgaggaagaaaagaaaacaaagacc
attgattctgttacttctgctcagatgctccaaggatgcaccatcttcaagggcaatttg
ctcattaacatccgacgggggaataacattgcttcagagctggagaacttcatggggctc
atcgaggtggtgacgggctacgtgaagatccgccattctcatgccttggtctccttgtcc
ttcctaaaaaaccttcgcctcatcctaggagaggagcagctagaagggaattactccttc
tacgtcctcgacaaccagaacttgcagcaactgtgggactgggaccaccgcaacctgacc
atcaaagcagggaaaatgtactttgctttcaatcccaaattatgtgtttccgaaatttac
cgcatggaggaagtgacggggactaaagggcgccaaagcaaaggggacataaacaccagg
aacaacggggagagagcctcctgtgaaagtgacgtcctgcatttcacctccaccaccacg
tcgaagaatcgcatcatcataacctggcaccggtaccggccccctgactacagggatctc
atcagcttcaccgtttactacaaggaagcaccctttaagaatgtcacagagtatgatggg
caggatgcctgcggctccaacagctggaacatggtggacgtggacctcccgcccaacaag
gacgtggagcccggcatcttactacatgggctgaagccctggactcagtacgccgtttac
gtcaaggctgtgaccctcaccatggtggagaacgaccatatccgtggggccaagagtgag
atcttgtacattcgcaccaatgcttcagttccttccattcccttggacgttctttcagca
tcgaactcctcttctcagttaatcgtgaagtggaaccctccctctctgcccaacggcaac
ctgagttactacattgtgcgctggcagcggcagcctcaggacggctacctttaccggcac
aattactgctccaaagacaaaatccccatcaggaagtatgccgacggcaccatcgacatt
gaggaggtcacagagaaccccaagactgaggtgtgtggtggggagaaagggccttgctgc
gcctgccccaaaactgaagccgagaagcaggccgagaaggaggaggctgaataccgcaaa
gtctttgagaatttcctgcacaactccatcttcgtgcccagacctgaaaggaagcggaga
gatgtcatgcaagtggccaacaccaccatgtccagccgaagcaggaacaccacggccgca
gacacctacaacatcaccgacccggaagagctggagacagagtaccctttctttgagagc
agagtggataacaaggagagaactgtcatttctaaccttcggcctttcacattgtaccgc
atcgatatccacagctgcaaccacgaggctgagaagctgggctgcagcgcctccaacttc
gtctttgcaaggactatgcccgcagaaggagcagatgacattcctgggccagtgacctgg
gagccaaggcctgaaaactccatctttttaaagtggccggaacctgagaatcccaatgga
ttgattctaatgtatgaaataaaatacggatcacaagttgaggatcagcgagaatgtgtg
tccagacaggaatacaggaagtatggaggggccaagctaaaccggctaaacccggggaac
tacacagcccggattcaggccacatctctctctgggaatgggtcgtggacagatcctgtg
ttcttctatgtccaggccaaaacaggatatgaaaacttcatccatctgatcatcgctctg
cccgtcgctgtcctgttgatcgtgggagggttggtgattatgctgtacgtcttccataga
aagagaaataacagcaggctggggaatggagtgctgtatgcctctgtgaacccggagtac
ttcagcgctgctgatgtgtacgttcctgatgagtgggaggtggctcgggagaagatcacc
atgagccgggaacttgggcaggggtcgtttgggatggtctatgaaggagttgccaagggt
gtggtgaaagatgaacctgaaaccagagtggccattaaaacagtgaacgaggccgcaagc
atgcgtgagaggattgagtttctcaacgaagcttctgtgatgaaggagttcaattgtcac
catgtggtgcgattgctgggtgtggtgtcccaaggccagccaacactggtcatcatggaa
ctgatgacacggggcgatctcaaaagttatctccggtctctgaggccagaaatggagaat
aatccagtcctagcacctccaagcctgagcaagatgattcagatggccggagagattgca
gacggcatggcatacctcaacgccaataagttcgtccacagagaccttgctgcccggaat
tgcatggtagccgaagatttcacagtcaaaatcggagattttggtatgacgcgagatatc
tatgagacagactattaccggaaaggagggaaagggctgctgcccgtgcgctggatgtct
cctgagtccctcaaggatggagtcttcaccacttactcggacgtctggtccttcggggtc
gtcctctgggagatcgccacactggccgagcagccctaccagggcttgtccaacgagcaa
gtccttcgcttcgtcatggagggcggccttctggacaagccagacaactgtcctgacatg
ctgtttgaactgatgcgcatgtgctggcagtataaccccaagatgaggccttccttcctg
gagatcatcagcagcatcaaagaggagatggagcctggcttccgggaggtctccttctac
tacagcgaggagaacaagctgcccgagccggaggagctggacctggagccagagaacatg
gagagcgtccccctggacccctcggcctcctcgtcctccctgccactgcccgacagacac
tcaggacacaaggccgagaacggccccggccctggggtgctggtcctccgcgccagcttc
gacgagagacagccttacgcccacatgaacgggggccgcaagaacgagcgggccttgccg
ctgccccagtcttcgacctgctga

KEGG   Homo sapiens (human): 3791
Entry
3791              CDS       T01001                                 
Symbol
KDR, CD309, FLK1, VEGFR, VEGFR2
Name
(RefSeq) kinase insert domain receptor
  KO
K05098  kinase insert domain protein receptor [EC:2.7.10.1]
Organism
hsa  Homo sapiens (human)
Pathway
hsa01521  EGFR tyrosine kinase inhibitor resistance
hsa04010  MAPK signaling pathway
hsa04014  Ras signaling pathway
hsa04015  Rap1 signaling pathway
hsa04020  Calcium signaling pathway
hsa04151  PI3K-Akt signaling pathway
hsa04370  VEGF signaling pathway
hsa04510  Focal adhesion
hsa05205  Proteoglycans in cancer
hsa05418  Fluid shear stress and atherosclerosis
Disease
H01482  Infantile hemangioma
Drug target
Altiratinib: D10862
Axitinib: D03218<JP/US>
Brivanib (DG01373): D08878 D09589
Cabozantinib (DG01670): D10062 D10095<JP/US>
Cediranib (DG01360): D08881 D08883
Dovitinib lactate: D08907
Foretinib: D09618
Fruquintinib: D11977
Golvatinib (DG01367): D10224 D10465
Lenvatinib (DG01362): D09919 D09920<JP/US>
Linifanib: D09635
Lucitanib: D11762
Midostaurin: D05029<US>
Motesanib (DG01262): D06678 D08947
Nintedanib (DG01374): D10396<JP/US> D10481
Pazopanib: D05380<JP/US>
Pegdinetanib: D09945
Ramucirumab: D09371<JP/US>
Regorafenib (DG00720): D10137<JP/US> D10138
Rivoceranib (DG02966): D11288 D11289
Semaxanib: D05819
Sitravatinib (DG03045): D11140 D11541
Sorafenib (DG00713): D06272<JP/US> D08524
Sunitinib (DG00712): D06402<JP/US> D08552
Surufatinib: D11885
Tesevatinib (DG03101): D11772 D11773
Tivozanib (DG01375): D09683 D10190<US>
Toceranib (DG01363): D08503 D08544
Vandetanib: D06407<JP/US>
Vatalanib: D06285
Brite
KEGG Orthology (KO) [BR:hsa00001]
 09130 Environmental Information Processing
  09132 Signal transduction
   04010 MAPK signaling pathway
    3791 (KDR)
   04014 Ras signaling pathway
    3791 (KDR)
   04015 Rap1 signaling pathway
    3791 (KDR)
   04370 VEGF signaling pathway
    3791 (KDR)
   04020 Calcium signaling pathway
    3791 (KDR)
   04151 PI3K-Akt signaling pathway
    3791 (KDR)
 09140 Cellular Processes
  09144 Cellular community - eukaryotes
   04510 Focal adhesion
    3791 (KDR)
 09160 Human Diseases
  09161 Cancer: overview
   05205 Proteoglycans in cancer
    3791 (KDR)
  09166 Cardiovascular disease
   05418 Fluid shear stress and atherosclerosis
    3791 (KDR)
  09176 Drug resistance: antineoplastic
   01521 EGFR tyrosine kinase inhibitor resistance
    3791 (KDR)
 09180 Brite Hierarchies
  09181 Protein families: metabolism
   01001 Protein kinases [BR:hsa01001]
    3791 (KDR)
  09183 Protein families: signaling and cellular processes
   04090 CD molecules [BR:hsa04090]
    3791 (KDR)
Enzymes [BR:hsa01000]
 2. Transferases
  2.7  Transferring phosphorus-containing groups
   2.7.10  Protein-tyrosine kinases
    2.7.10.1  receptor protein-tyrosine kinase
     3791 (KDR)
Protein kinases [BR:hsa01001]
 Receptor tyrosine kinases (RTK)
  VEGFR family [OT]
   3791 (KDR)
CD molecules [BR:hsa04090]
 Proteins
  3791 (KDR)
SSDB
Motif
Pfam: PK_Tyr_Ser-Thr Ig_3 I-set Pkinase Ig_2 ig VEGFR-2_TMD V-set C2-set_2 Ig_4 Haspin_kinase
Other DBs
NCBI-GeneID: 3791
NCBI-ProteinID: NP_002244
OMIM: 191306
HGNC: 6307
Ensembl: ENSG00000128052
Pharos: P35968(Tclin)
UniProt: P35968
Structure
LinkDB
Position
4:complement(55078481..55125595)
AA seq 1356 aa
MQSKVLLAVALWLCVETRAASVGLPSVSLDLPRLSIQKDILTIKANTTLQITCRGQRDLD
WLWPNNQSGSEQRVEVTECSDGLFCKTLTIPKVIGNDTGAYKCFYRETDLASVIYVYVQD
YRSPFIASVSDQHGVVYITENKNKTVVIPCLGSISNLNVSLCARYPEKRFVPDGNRISWD
SKKGFTIPSYMISYAGMVFCEAKINDESYQSIMYIVVVVGYRIYDVVLSPSHGIELSVGE
KLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRS
DQGLYTCAASSGLMTKKNSTFVRVHEKPFVAFGSGMESLVEATVGERVRIPAKYLGYPPP
EIKWYKNGIPLESNHTIKAGHVLTIMEVSERDTGNYTVILTNPISKEKQSHVVSLVVYVP
PQIGEKSLISPVDSYQYGTTQTLTCTVYAIPPPHHIHWYWQLEEECANEPSQAVSVTNPY
PCEEWRSVEDFQGGNKIEVNKNQFALIEGKNKTVSTLVIQAANVSALYKCEAVNKVGRGE
RVISFHVTRGPEITLQPDMQPTEQESVSLWCTADRSTFENLTWYKLGPQPLPIHVGELPT
PVCKNLDTLWKLNATMFSNSTNDILIMELKNASLQDQGDYVCLAQDRKTKKRHCVVRQLT
VLERVAPTITGNLENQTTSIGESIEVSCTASGNPPPQIMWFKDNETLVEDSGIVLKDGNR
NLTIRRVRKEDEGLYTCQACSVLGCAKVEAFFIIEGAQEKTNLEIIILVGTAVIAMFFWL
LLVIILRTVKRANGGELKTGYLSIVMDPDELPLDEHCERLPYDASKWEFPRDRLKLGKPL
GRGAFGQVIEADAFGIDKTATCRTVAVKMLKEGATHSEHRALMSELKILIHIGHHLNVVN
LLGACTKPGGPLMVIVEFCKFGNLSTYLRSKRNEFVPYKTKGARFRQGKDYVGAIPVDLK
RRLDSITSSQSSASSGFVEEKSLSDVEEEEAPEDLYKDFLTLEHLICYSFQVAKGMEFLA
SRKCIHRDLAARNILLSEKNVVKICDFGLARDIYKDPDYVRKGDARLPLKWMAPETIFDR
VYTIQSDVWSFGVLLWEIFSLGASPYPGVKIDEEFCRRLKEGTRMRAPDYTTPEMYQTML
DCWHGEPSQRPTFSELVEHLGNLLQANAQQDGKDYIVLPISETLSMEEDSGLSLPTSPVS
CMEEEEVCDPKFHYDNTAGISQYLQNSKRKSRPVSVKTFEDIPLEEPEVKVIPDDNQTDS
GMVLASEELKTLEDRTKLSPSFGGMVPSKSRESVASEGSNQTSGYQSGYHSDDTDTTVYS
SEEAELLKLIEIGVQTGSTAQILQPDSGTTLSSPPV
NT seq 4071 nt   +upstreamnt  +downstreamnt
atgcagagcaaggtgctgctggccgtcgccctgtggctctgcgtggagacccgggccgcc
tctgtgggtttgcctagtgtttctcttgatctgcccaggctcagcatacaaaaagacata
cttacaattaaggctaatacaactcttcaaattacttgcaggggacagagggacttggac
tggctttggcccaataatcagagtggcagtgagcaaagggtggaggtgactgagtgcagc
gatggcctcttctgtaagacactcacaattccaaaagtgatcggaaatgacactggagcc
tacaagtgcttctaccgggaaactgacttggcctcggtcatttatgtctatgttcaagat
tacagatctccatttattgcttctgttagtgaccaacatggagtcgtgtacattactgag
aacaaaaacaaaactgtggtgattccatgtctcgggtccatttcaaatctcaacgtgtca
ctttgtgcaagatacccagaaaagagatttgttcctgatggtaacagaatttcctgggac
agcaagaagggctttactattcccagctacatgatcagctatgctggcatggtcttctgt
gaagcaaaaattaatgatgaaagttaccagtctattatgtacatagttgtcgttgtaggg
tataggatttatgatgtggttctgagtccgtctcatggaattgaactatctgttggagaa
aagcttgtcttaaattgtacagcaagaactgaactaaatgtggggattgacttcaactgg
gaatacccttcttcgaagcatcagcataagaaacttgtaaaccgagacctaaaaacccag
tctgggagtgagatgaagaaatttttgagcaccttaactatagatggtgtaacccggagt
gaccaaggattgtacacctgtgcagcatccagtgggctgatgaccaagaagaacagcaca
tttgtcagggtccatgaaaaaccttttgttgcttttggaagtggcatggaatctctggtg
gaagccacggtgggggagcgtgtcagaatccctgcgaagtaccttggttacccaccccca
gaaataaaatggtataaaaatggaataccccttgagtccaatcacacaattaaagcgggg
catgtactgacgattatggaagtgagtgaaagagacacaggaaattacactgtcatcctt
accaatcccatttcaaaggagaagcagagccatgtggtctctctggttgtgtatgtccca
ccccagattggtgagaaatctctaatctctcctgtggattcctaccagtacggcaccact
caaacgctgacatgtacggtctatgccattcctcccccgcatcacatccactggtattgg
cagttggaggaagagtgcgccaacgagcccagccaagctgtctcagtgacaaacccatac
ccttgtgaagaatggagaagtgtggaggacttccagggaggaaataaaattgaagttaat
aaaaatcaatttgctctaattgaaggaaaaaacaaaactgtaagtacccttgttatccaa
gcggcaaatgtgtcagctttgtacaaatgtgaagcggtcaacaaagtcgggagaggagag
agggtgatctccttccacgtgaccaggggtcctgaaattactttgcaacctgacatgcag
cccactgagcaggagagcgtgtctttgtggtgcactgcagacagatctacgtttgagaac
ctcacatggtacaagcttggcccacagcctctgccaatccatgtgggagagttgcccaca
cctgtttgcaagaacttggatactctttggaaattgaatgccaccatgttctctaatagc
acaaatgacattttgatcatggagcttaagaatgcatccttgcaggaccaaggagactat
gtctgccttgctcaagacaggaagaccaagaaaagacattgcgtggtcaggcagctcaca
gtcctagagcgtgtggcacccacgatcacaggaaacctggagaatcagacgacaagtatt
ggggaaagcatcgaagtctcatgcacggcatctgggaatccccctccacagatcatgtgg
tttaaagataatgagacccttgtagaagactcaggcattgtattgaaggatgggaaccgg
aacctcactatccgcagagtgaggaaggaggacgaaggcctctacacctgccaggcatgc
agtgttcttggctgtgcaaaagtggaggcatttttcataatagaaggtgcccaggaaaag
acgaacttggaaatcattattctagtaggcacggcggtgattgccatgttcttctggcta
cttcttgtcatcatcctacggaccgttaagcgggccaatggaggggaactgaagacaggc
tacttgtccatcgtcatggatccagatgaactcccattggatgaacattgtgaacgactg
ccttatgatgccagcaaatgggaattccccagagaccggctgaagctaggtaagcctctt
ggccgtggtgcctttggccaagtgattgaagcagatgcctttggaattgacaagacagca
acttgcaggacagtagcagtcaaaatgttgaaagaaggagcaacacacagtgagcatcga
gctctcatgtctgaactcaagatcctcattcatattggtcaccatctcaatgtggtcaac
cttctaggtgcctgtaccaagccaggagggccactcatggtgattgtggaattctgcaaa
tttggaaacctgtccacttacctgaggagcaagagaaatgaatttgtcccctacaagacc
aaaggggcacgattccgtcaagggaaagactacgttggagcaatccctgtggatctgaaa
cggcgcttggacagcatcaccagtagccagagctcagccagctctggatttgtggaggag
aagtccctcagtgatgtagaagaagaggaagctcctgaagatctgtataaggacttcctg
accttggagcatctcatctgttacagcttccaagtggctaagggcatggagttcttggca
tcgcgaaagtgtatccacagggacctggcggcacgaaatatcctcttatcggagaagaac
gtggttaaaatctgtgactttggcttggcccgggatatttataaagatccagattatgtc
agaaaaggagatgctcgcctccctttgaaatggatggccccagaaacaatttttgacaga
gtgtacacaatccagagtgacgtctggtcttttggtgttttgctgtgggaaatattttcc
ttaggtgcttctccatatcctggggtaaagattgatgaagaattttgtaggcgattgaaa
gaaggaactagaatgagggcccctgattatactacaccagaaatgtaccagaccatgctg
gactgctggcacggggagcccagtcagagacccacgttttcagagttggtggaacatttg
ggaaatctcttgcaagctaatgctcagcaggatggcaaagactacattgttcttccgata
tcagagactttgagcatggaagaggattctggactctctctgcctacctcacctgtttcc
tgtatggaggaggaggaagtatgtgaccccaaattccattatgacaacacagcaggaatc
agtcagtatctgcagaacagtaagcgaaagagccggcctgtgagtgtaaaaacatttgaa
gatatcccgttagaagaaccagaagtaaaagtaatcccagatgacaaccagacggacagt
ggtatggttcttgcctcagaagagctgaaaactttggaagacagaaccaaattatctcca
tcttttggtggaatggtgcccagcaaaagcagggagtctgtggcatctgaaggctcaaac
cagacaagcggctaccagtccggatatcactccgatgacacagacaccaccgtgtactcc
agtgaggaagcagaacttttaaagctgatagagattggagtgcaaaccggtagcacagcc
cagattctccagcctgactcggggaccacactgagctctcctcctgtttaa

KEGG   Homo sapiens (human): 4233
Entry
4233              CDS       T01001                                 
Symbol
MET, AUTS9, DFNB97, HGFR, RCCP2, c-Met
Name
(RefSeq) MET proto-oncogene, receptor tyrosine kinase
  KO
K05099  proto-oncogene tyrosine-protein kinase Met [EC:2.7.10.1]
Organism
hsa  Homo sapiens (human)
Pathway
hsa01521  EGFR tyrosine kinase inhibitor resistance
hsa04010  MAPK signaling pathway
hsa04014  Ras signaling pathway
hsa04015  Rap1 signaling pathway
hsa04020  Calcium signaling pathway
hsa04151  PI3K-Akt signaling pathway
hsa04360  Axon guidance
hsa04510  Focal adhesion
hsa04520  Adherens junction
hsa05100  Bacterial invasion of epithelial cells
hsa05120  Epithelial cell signaling in Helicobacter pylori infection
hsa05144  Malaria
hsa05200  Pathways in cancer
hsa05202  Transcriptional misregulation in cancer
hsa05205  Proteoglycans in cancer
hsa05206  MicroRNAs in cancer
hsa05208  Chemical carcinogenesis - reactive oxygen species
hsa05211  Renal cell carcinoma
hsa05218  Melanoma
hsa05223  Non-small cell lung cancer
hsa05225  Hepatocellular carcinoma
hsa05226  Gastric cancer
hsa05230  Central carbon metabolism in cancer
Network
nt06110  MAPK signaling (viruses and bacteria)
nt06162  Hepatitis B virus (HBV)
nt06163  Hepatitis C virus (HCV)
nt06164  Kaposi sarcoma-associated herpesvirus (KSHV)
nt06210  ERK signaling
nt06214  PI3K signaling
nt06240  Transcription
nt06261  Gastric cancer
nt06262  Pancreatic cancer
nt06263  Hepatocellular carcinoma
nt06264  Renal cell carcinoma
nt06266  Non-small cell lung cancer
  Element
N00005  Mutation-activated MET to RAS-ERK signaling pathway
N00043  HGF-MET-PI3K signaling pathway
N00044  Mutation-activated MET to PI3K signaling pathway
N00143  ASPL-TFE3 fusion to transcriptional activation
N00216  HGF-MET-RAS-ERK signaling pathway
N00246  HGF-overexpression to RAS-ERK signaling pathway
N00247  HGF-overexpression to PI3K signaling pathway
N00248  MET-overexpression to RAS-ERK signaling pathway
N00249  MET-overexpression to PI3K signaling pathway
N00259  Amplified MET to RAS-ERK signaling pathway
N00260  Amplified MET to PI3K signaling pathway
N01062  Mutation-activated MET to RAS-ERK signaling pathway
N01063  Mutation-activated MET to PI3K signaling pathway
N10024  Tyrosine kinase inhibitor to MET exon 14 skipping
Disease
H00014  Non-small cell lung cancer
H00018  Gastric cancer
H00021  Renal cell carcinoma
H00046  Cholangiocarcinoma
H00048  Hepatocellular carcinoma
H00605  Deafness, autosomal recessive
H01985  Desmoplastic small round cell tumor
Drug target
Altiratinib: D10862
Amivantamab: D11894<US>
Amuvatinib (DG01916): D09864 D09865
Cabozantinib (DG01670): D10062 D10095<JP/US>
Capmatinib (DG02081): D10696 D10891<JP/US>
Foretinib: D09618
Glesatinib: D11136
Golvatinib (DG01367): D10224 D10465
Merestinib: D11763
Onartuzumab: D09941
Savolitinib: D11139
Sitravatinib (DG03045): D11140 D11541
Telisotuzumab: D11307
Telisotuzumab vedotin: D11344
Tepotinib (DG03087): D11073<JP/US> D11717
Terevalefim: D12287
Tivantinib: D10173
Vebreltinib: D12053
Brite
KEGG Orthology (KO) [BR:hsa00001]
 09130 Environmental Information Processing
  09132 Signal transduction
   04010 MAPK signaling pathway
    4233 (MET)
   04014 Ras signaling pathway
    4233 (MET)
   04015 Rap1 signaling pathway
    4233 (MET)
   04020 Calcium signaling pathway
    4233 (MET)
   04151 PI3K-Akt signaling pathway
    4233 (MET)
 09140 Cellular Processes
  09144 Cellular community - eukaryotes
   04510 Focal adhesion
    4233 (MET)
   04520 Adherens junction
    4233 (MET)
 09150 Organismal Systems
  09158 Development and regeneration
   04360 Axon guidance
    4233 (MET)
 09160 Human Diseases
  09161 Cancer: overview
   05200 Pathways in cancer
    4233 (MET)
   05202 Transcriptional misregulation in cancer
    4233 (MET)
   05206 MicroRNAs in cancer
    4233 (MET)
   05205 Proteoglycans in cancer
    4233 (MET)
   05208 Chemical carcinogenesis - reactive oxygen species
    4233 (MET)
   05230 Central carbon metabolism in cancer
    4233 (MET)
  09162 Cancer: specific types
   05225 Hepatocellular carcinoma
    4233 (MET)
   05226 Gastric cancer
    4233 (MET)
   05218 Melanoma
    4233 (MET)
   05211 Renal cell carcinoma
    4233 (MET)
   05223 Non-small cell lung cancer
    4233 (MET)
  09171 Infectious disease: bacterial
   05120 Epithelial cell signaling in Helicobacter pylori infection
    4233 (MET)
   05100 Bacterial invasion of epithelial cells
    4233 (MET)
  09174 Infectious disease: parasitic
   05144 Malaria
    4233 (MET)
  09176 Drug resistance: antineoplastic
   01521 EGFR tyrosine kinase inhibitor resistance
    4233 (MET)
 09180 Brite Hierarchies
  09181 Protein families: metabolism
   01001 Protein kinases [BR:hsa01001]
    4233 (MET)
Enzymes [BR:hsa01000]
 2. Transferases
  2.7  Transferring phosphorus-containing groups
   2.7.10  Protein-tyrosine kinases
    2.7.10.1  receptor protein-tyrosine kinase
     4233 (MET)
Protein kinases [BR:hsa01001]
 Receptor tyrosine kinases (RTK)
  MET family
   4233 (MET)
SSDB
Motif
Pfam: PK_Tyr_Ser-Thr TIG Pkinase Sema PSI Kinase-like Pkinase_fungal
Other DBs
NCBI-GeneID: 4233
NCBI-ProteinID: NP_000236
OMIM: 164860
HGNC: 7029
Ensembl: ENSG00000105976
Pharos: P08581(Tclin)
UniProt: P08581 A0A024R759
Structure
LinkDB
Position
7:116672196..116798377
AA seq 1390 aa
MKAPAVLAPGILVLLFTLVQRSNGECKEALAKSEMNVNMKYQLPNFTAETPIQNVILHEH
HIFLGATNYIYVLNEEDLQKVAEYKTGPVLEHPDCFPCQDCSSKANLSGGVWKDNINMAL
VVDTYYDDQLISCGSVNRGTCQRHVFPHNHTADIQSEVHCIFSPQIEEPSQCPDCVVSAL
GAKVLSSVKDRFINFFVGNTINSSYFPDHPLHSISVRRLKETKDGFMFLTDQSYIDVLPE
FRDSYPIKYVHAFESNNFIYFLTVQRETLDAQTFHTRIIRFCSINSGLHSYMEMPLECIL
TEKRKKRSTKKEVFNILQAAYVSKPGAQLARQIGASLNDDILFGVFAQSKPDSAEPMDRS
AMCAFPIKYVNDFFNKIVNKNNVRCLQHFYGPNHEHCFNRTLLRNSSGCEARRDEYRTEF
TTALQRVDLFMGQFSEVLLTSISTFIKGDLTIANLGTSEGRFMQVVVSRSGPSTPHVNFL
LDSHPVSPEVIVEHTLNQNGYTLVITGKKITKIPLNGLGCRHFQSCSQCLSAPPFVQCGW
CHDKCVRSEECLSGTWTQQICLPAIYKVFPNSAPLEGGTRLTICGWDFGFRRNNKFDLKK
TRVLLGNESCTLTLSESTMNTLKCTVGPAMNKHFNMSIIISNGHGTTQYSTFSYVDPVIT
SISPKYGPMAGGTLLTLTGNYLNSGNSRHISIGGKTCTLKSVSNSILECYTPAQTISTEF
AVKLKIDLANRETSIFSYREDPIVYEIHPTKSFISGGSTITGVGKNLNSVSVPRMVINVH
EAGRNFTVACQHRSNSEIICCTTPSLQQLNLQLPLKTKAFFMLDGILSKYFDLIYVHNPV
FKPFEKPVMISMGNENVLEIKGNDIDPEAVKGEVLKVGNKSCENIHLHSEAVLCTVPNDL
LKLNSELNIEWKQAISSTVLGKVIVQPDQNFTGLIAGVVSISTALLLLLGFFLWLKKRKQ
IKDLGSELVRYDARVHTPHLDRLVSARSVSPTTEMVSNESVDYRATFPEDQFPNSSQNGS
CRQVQYPLTDMSPILTSGDSDISSPLLQNTVHIDLSALNPELVQAVQHVVIGPSSLIVHF
NEVIGRGHFGCVYHGTLLDNDGKKIHCAVKSLNRITDIGEVSQFLTEGIIMKDFSHPNVL
SLLGICLRSEGSPLVVLPYMKHGDLRNFIRNETHNPTVKDLIGFGLQVAKGMKYLASKKF
VHRDLAARNCMLDEKFTVKVADFGLARDMYDKEYYSVHNKTGAKLPVKWMALESLQTQKF
TTKSDVWSFGVLLWELMTRGAPPYPDVNTFDITVYLLQGRRLLQPEYCPDPLYEVMLKCW
HPKAEMRPSFSELVSRISAIFSTFIGEHYVHVNATYVNVKCVAPYPSLLSSEDNADDEVD
TRPASFWETS
NT seq 4173 nt   +upstreamnt  +downstreamnt
atgaaggcccccgctgtgcttgcacctggcatcctcgtgctcctgtttaccttggtgcag
aggagcaatggggagtgtaaagaggcactagcaaagtccgagatgaatgtgaatatgaag
tatcagcttcccaacttcaccgcggaaacacccatccagaatgtcattctacatgagcat
cacattttccttggtgccactaactacatttatgttttaaatgaggaagaccttcagaag
gttgctgagtacaagactgggcctgtgctggaacacccagattgtttcccatgtcaggac
tgcagcagcaaagccaatttatcaggaggtgtttggaaagataacatcaacatggctcta
gttgtcgacacctactatgatgatcaactcattagctgtggcagcgtcaacagagggacc
tgccagcgacatgtctttccccacaatcatactgctgacatacagtcggaggttcactgc
atattctccccacagatagaagagcccagccagtgtcctgactgtgtggtgagcgccctg
ggagccaaagtcctttcatctgtaaaggaccggttcatcaacttctttgtaggcaatacc
ataaattcttcttatttcccagatcatccattgcattcgatatcagtgagaaggctaaag
gaaacgaaagatggttttatgtttttgacggaccagtcctacattgatgttttacctgag
ttcagagattcttaccccattaagtatgtccatgcctttgaaagcaacaattttatttac
ttcttgacggtccaaagggaaactctagatgctcagacttttcacacaagaataatcagg
ttctgttccataaactctggattgcattcctacatggaaatgcctctggagtgtattctc
acagaaaagagaaaaaagagatccacaaagaaggaagtgtttaatatacttcaggctgcg
tatgtcagcaagcctggggcccagcttgctagacaaataggagccagcctgaatgatgac
attcttttcggggtgttcgcacaaagcaagccagattctgccgaaccaatggatcgatct
gccatgtgtgcattccctatcaaatatgtcaacgacttcttcaacaagatcgtcaacaaa
aacaatgtgagatgtctccagcatttttacggacccaatcatgagcactgctttaatagg
acacttctgagaaattcatcaggctgtgaagcgcgccgtgatgaatatcgaacagagttt
accacagctttgcagcgcgttgacttattcatgggtcaattcagcgaagtcctcttaaca
tctatatccaccttcattaaaggagacctcaccatagctaatcttgggacatcagagggt
cgcttcatgcaggttgtggtttctcgatcaggaccatcaacccctcatgtgaattttctc
ctggactcccatccagtgtctccagaagtgattgtggagcatacattaaaccaaaatggc
tacacactggttatcactgggaagaagatcacgaagatcccattgaatggcttgggctgc
agacatttccagtcctgcagtcaatgcctctctgccccaccctttgttcagtgtggctgg
tgccacgacaaatgtgtgcgatcggaggaatgcctgagcgggacatggactcaacagatc
tgtctgcctgcaatctacaaggttttcccaaatagtgcaccccttgaaggagggacaagg
ctgaccatatgtggctgggactttggatttcggaggaataataaatttgatttaaagaaa
actagagttctccttggaaatgagagctgcaccttgactttaagtgagagcacgatgaat
acattgaaatgcacagttggtcctgccatgaataagcatttcaatatgtccataattatt
tcaaatggccacgggacaacacaatacagtacattctcctatgtggatcctgtaataaca
agtatttcgccgaaatacggtcctatggctggtggcactttacttactttaactggaaat
tacctaaacagtgggaattctagacacatttcaattggtggaaaaacatgtactttaaaa
agtgtgtcaaacagtattcttgaatgttataccccagcccaaaccatttcaactgagttt
gctgttaaattgaaaattgacttagccaaccgagagacaagcatcttcagttaccgtgaa
gatcccattgtctatgaaattcatccaaccaaatcttttattagtggtgggagcacaata
acaggtgttgggaaaaacctgaattcagttagtgtcccgagaatggtcataaatgtgcat
gaagcaggaaggaactttacagtggcatgtcaacatcgctctaattcagagataatctgt
tgtaccactccttccctgcaacagctgaatctgcaactccccctgaaaaccaaagccttt
ttcatgttagatgggatcctttccaaatactttgatctcatttatgtacataatcctgtg
tttaagccttttgaaaagccagtgatgatctcaatgggcaatgaaaatgtactggaaatt
aagggaaatgatattgaccctgaagcagttaaaggtgaagtgttaaaagttggaaataag
agctgtgagaatatacacttacattctgaagccgttttatgcacggtccccaatgacctg
ctgaaattgaacagcgagctaaatatagagtggaagcaagcaatttcttcaaccgtcctt
ggaaaagtaatagttcaaccagatcagaatttcacaggattgattgctggtgttgtctca
atatcaacagcactgttattactacttgggtttttcctgtggctgaaaaagagaaagcaa
attaaagatctgggcagtgaattagttcgctacgatgcaagagtacacactcctcatttg
gataggcttgtaagtgcccgaagtgtaagcccaactacagaaatggtttcaaatgaatct
gtagactaccgagctacttttccagaagatcagtttcctaattcatctcagaacggttca
tgccgacaagtgcagtatcctctgacagacatgtcccccatcctaactagtggggactct
gatatatccagtccattactgcaaaatactgtccacattgacctcagtgctctaaatcca
gagctggtccaggcagtgcagcatgtagtgattgggcccagtagcctgattgtgcatttc
aatgaagtcataggaagagggcattttggttgtgtatatcatgggactttgttggacaat
gatggcaagaaaattcactgtgctgtgaaatccttgaacagaatcactgacataggagaa
gtttcccaatttctgaccgagggaatcatcatgaaagattttagtcatcccaatgtcctc
tcgctcctgggaatctgcctgcgaagtgaagggtctccgctggtggtcctaccatacatg
aaacatggagatcttcgaaatttcattcgaaatgagactcataatccaactgtaaaagat
cttattggctttggtcttcaagtagccaaaggcatgaaatatcttgcaagcaaaaagttt
gtccacagagacttggctgcaagaaactgtatgctggatgaaaaattcacagtcaaggtt
gctgattttggtcttgccagagacatgtatgataaagaatactatagtgtacacaacaaa
acaggtgcaaagctgccagtgaagtggatggctttggaaagtctgcaaactcaaaagttt
accaccaagtcagatgtgtggtcctttggcgtgctcctctgggagctgatgacaagagga
gccccaccttatcctgacgtaaacacctttgatataactgtttacttgttgcaagggaga
agactcctacaacccgaatactgcccagaccccttatatgaagtaatgctaaaatgctgg
caccctaaagccgaaatgcgcccatccttttctgaactggtgtcccggatatcagcgatc
ttctctactttcattggggagcactatgtccatgtgaacgctacttatgtgaacgtaaaa
tgtgtcgctccgtatccttctctgttgtcatcagaagataacgctgatgatgaggtggac
acacgaccagcctccttctgggagacatcatag

KEGG   Homo sapiens (human): 5156
Entry
5156              CDS       T01001                                 
Symbol
PDGFRA, CD140A, PDGFR-2, PDGFR2
Name
(RefSeq) platelet derived growth factor receptor alpha
  KO
K04363  platelet-derived growth factor receptor alpha [EC:2.7.10.1]
Organism
hsa  Homo sapiens (human)
Pathway
hsa01521  EGFR tyrosine kinase inhibitor resistance
hsa04010  MAPK signaling pathway
hsa04014  Ras signaling pathway
hsa04015  Rap1 signaling pathway
hsa04020  Calcium signaling pathway
hsa04072  Phospholipase D signaling pathway
hsa04144  Endocytosis
hsa04151  PI3K-Akt signaling pathway
hsa04510  Focal adhesion
hsa04540  Gap junction
hsa04630  JAK-STAT signaling pathway
hsa04810  Regulation of actin cytoskeleton
hsa05163  Human cytomegalovirus infection
hsa05200  Pathways in cancer
hsa05206  MicroRNAs in cancer
hsa05214  Glioma
hsa05215  Prostate cancer
hsa05218  Melanoma
hsa05230  Central carbon metabolism in cancer
hsa05231  Choline metabolism in cancer
Network
nt06110  MAPK signaling (viruses and bacteria)
nt06114  PI3K signaling (viruses)
nt06166  Human papillomavirus (HPV)
nt06167  Human cytomegalovirus (HCMV)
nt06210  ERK signaling
nt06214  PI3K signaling
nt06220  Calcium signaling
nt06273  Glioma
  Element
N00015  PDGF-PDGFR-RAS-ERK signaling pathway
N00016  PDGF-overexpression to RAS-ERK signaling pathway
N00018  Amplified PDGFR to RAS-ERK signaling pathway
N00028  PDGF-PDGFR-PLCG-CAMK signaling pathway
N00029  Amplified PDGFR to PLCG-CAMK signaling pathway
N00039  PDGF-PDGFR-PI3K signaling pathway
N00040  Amplified PDGFR to PI3K signaling pathway
N00385  HCMV gB to PDGFR-PI3K signaling pathway
N00386  HCMV gB to PDGFR-RAS-ERK signaling pathway
Disease
H00042  Glioma
H01590  Chronic eosinophilic leukemia
H01591  Gastrotintestinal stromal tumor
H01599  Hypereosinophilic syndrome
Drug target
Avapritinib: D11279<US>
Crenolanib (DG01361): D10102 D10103
Ilorasertib: D10423
Imatinib (DG00710): D01441<JP/US> D08066
Linifanib: D09635
Midostaurin: D05029<US>
Motesanib (DG01262): D06678 D08947
Nilotinib (DG00716): D06413<JP/US> D08953
Nintedanib (DG01374): D10396<JP/US> D10481
Olaratumab: D09939
Pazopanib: D05380<JP/US>
Ripretinib: D11353<US>
Seralutinib: D12002
Sitravatinib (DG03045): D11140 D11541
Sunitinib (DG00712): D06402<JP/US> D08552
Toceranib (DG01363): D08503 D08544
Tovetumab: D10411
Brite
KEGG Orthology (KO) [BR:hsa00001]
 09130 Environmental Information Processing
  09132 Signal transduction
   04010 MAPK signaling pathway
    5156 (PDGFRA)
   04014 Ras signaling pathway
    5156 (PDGFRA)
   04015 Rap1 signaling pathway
    5156 (PDGFRA)
   04630 JAK-STAT signaling pathway
    5156 (PDGFRA)
   04020 Calcium signaling pathway
    5156 (PDGFRA)
   04072 Phospholipase D signaling pathway
    5156 (PDGFRA)
   04151 PI3K-Akt signaling pathway
    5156 (PDGFRA)
 09140 Cellular Processes
  09141 Transport and catabolism
   04144 Endocytosis
    5156 (PDGFRA)
  09144 Cellular community - eukaryotes
   04510 Focal adhesion
    5156 (PDGFRA)
   04540 Gap junction
    5156 (PDGFRA)
  09142 Cell motility
   04810 Regulation of actin cytoskeleton
    5156 (PDGFRA)
 09160 Human Diseases
  09161 Cancer: overview
   05200 Pathways in cancer
    5156 (PDGFRA)
   05206 MicroRNAs in cancer
    5156 (PDGFRA)
   05230 Central carbon metabolism in cancer
    5156 (PDGFRA)
   05231 Choline metabolism in cancer
    5156 (PDGFRA)
  09162 Cancer: specific types
   05214 Glioma
    5156 (PDGFRA)
   05218 Melanoma
    5156 (PDGFRA)
   05215 Prostate cancer
    5156 (PDGFRA)
  09172 Infectious disease: viral
   05163 Human cytomegalovirus infection
    5156 (PDGFRA)
  09176 Drug resistance: antineoplastic
   01521 EGFR tyrosine kinase inhibitor resistance
    5156 (PDGFRA)
 09180 Brite Hierarchies
  09181 Protein families: metabolism
   01001 Protein kinases [BR:hsa01001]
    5156 (PDGFRA)
  09183 Protein families: signaling and cellular processes
   04090 CD molecules [BR:hsa04090]
    5156 (PDGFRA)
Enzymes [BR:hsa01000]
 2. Transferases
  2.7  Transferring phosphorus-containing groups
   2.7.10  Protein-tyrosine kinases
    2.7.10.1  receptor protein-tyrosine kinase
     5156 (PDGFRA)
Protein kinases [BR:hsa01001]
 Receptor tyrosine kinases (RTK)
  PDGFR family [OT]
   5156 (PDGFRA)
CD molecules [BR:hsa04090]
 Proteins
  5156 (PDGFRA)
SSDB
Motif
Pfam: PK_Tyr_Ser-Thr Pkinase Ig_3 I-set ig Ig_2 V-set C2-set_2 Kinase-like
Other DBs
NCBI-GeneID: 5156
NCBI-ProteinID: NP_001334758
OMIM: 173490
HGNC: 8803
Ensembl: ENSG00000134853
Pharos: P16234(Tclin)
UniProt: P16234
Structure
LinkDB
Position
4:54229293..54298245
AA seq 1089 aa
MGTSHPAFLVLGCLLTGLSLILCQLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYP
MSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIY
VPDPDVAFVPLGMTDYLVIVEDDDSAIIPCRTTDPETPVTLHNSEGVVPASYDSRQGFNG
TFTVGPYICEATVKGKKFQTIPFNVYALKATSELDLEMEALKTVYKSGETIVVTCAVFNN
EVVDLQWTYPGEVKGKGITMLEEIKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVK
EMKKVTISVHEKGFIEIKPTFSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENL
TEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDL
VDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRD
RSTVEGRVTFAKVEETIAVRCLAKNLLGAENRELKLVAPTLRSELTVAAAVLVLLVIVII
SLIVLVVIWKQKPRYEIRWRVIESISPDGHEYIYVDPMQLPYDSRWEFPRDGLVLGRVLG
SGAFGKVVEGTAYGLSRSQPVMKVAVKMLKPTARSSEKQALMSELKIMTHLGPHLNIVNL
LGACTKSGPIYIITEYCFYGDLVNYLHKNRDSFLSHHPEKPKKELDIFGLNPADESTRSY
VILSFENNGDYMDMKQADTTQYVPMLERKEVSKYSDIQRSLYDRPASYKKKSMLDSEVKN
LLSDDNSEGLTLLDLLSFTYQVARGMEFLASKNCVHRDLAARNVLLAQGKIVKICDFGLA
RDIMHDSNYVSKGSTFLPVKWMAPESIFDNLYTTLSDVWSYGILLWEIFSLGGTPYPGMM
VDSTFYNKIKSGYRMAKPDHATSEVYEIMVKCWNSEPEKRPSFYHLSEIVENLLPGQYKK
SYEKIHLDFLKSDHPAVARMRVDSDNAYIGVTYKNEEDKLKDWEGGLDEQRLSADSGYII
PLPDIDPVPEEEDLGKRNRHSSQTSEESAIETGSSSSTFIKREDETIEDIDMMDDIGIDS
SDLVEDSFL
NT seq 3270 nt   +upstreamnt  +downstreamnt
atggggacttcccatccggcgttcctggtcttaggctgtcttctcacagggctgagccta
atcctctgccagctttcattaccctctatccttccaaatgaaaatgaaaaggttgtgcag
ctgaattcatccttttctctgagatgctttggggagagtgaagtgagctggcagtacccc
atgtctgaagaagagagctccgatgtggaaatcagaaatgaagaaaacaacagcggcctt
tttgtgacggtcttggaagtgagcagtgcctcggcggcccacacagggttgtacacttgc
tattacaaccacactcagacagaagagaatgagcttgaaggcaggcacatttacatctat
gtgccagacccagatgtagcctttgtacctctaggaatgacggattatttagtcatcgtg
gaggatgatgattctgccattataccttgtcgcacaactgatcccgagactcctgtaacc
ttacacaacagtgagggggtggtacctgcctcctacgacagcagacagggctttaatggg
accttcactgtagggccctatatctgtgaggccaccgtcaaaggaaagaagttccagacc
atcccatttaatgtttatgctttaaaagcaacatcagagctggatctagaaatggaagct
cttaaaaccgtgtataagtcaggggaaacgattgtggtcacctgtgctgtttttaacaat
gaggtggttgaccttcaatggacttaccctggagaagtgaaaggcaaaggcatcacaatg
ctggaagaaatcaaagtcccatccatcaaattggtgtacactttgacggtccccgaggcc
acggtgaaagacagtggagattacgaatgtgctgcccgccaggctaccagggaggtcaaa
gaaatgaagaaagtcactatttctgtccatgagaaaggtttcattgaaatcaaacccacc
ttcagccagttggaagctgtcaacctgcatgaagtcaaacattttgttgtagaggtgcgg
gcctacccacctcccaggatatcctggctgaaaaacaatctgactctgattgaaaatctc
actgagatcaccactgatgtggaaaagattcaggaaataaggtatcgaagcaaattaaag
ctgatccgtgctaaggaagaagacagtggccattatactattgtagctcaaaatgaagat
gctgtgaagagctatacttttgaactgttaactcaagttccttcatccattctggacttg
gtcgatgatcaccatggctcaactgggggacagacggtgaggtgcacagctgaaggcacg
ccgcttcctgatattgagtggatgatatgcaaagatattaagaaatgtaataatgaaact
tcctggactattttggccaacaatgtctcaaacatcatcacggagatccactcccgagac
aggagtaccgtggagggccgtgtgactttcgccaaagtggaggagaccatcgccgtgcga
tgcctggctaagaatctccttggagctgagaaccgagagctgaagctggtggctcccacc
ctgcgttctgaactcacggtggctgctgcagtcctggtgctgttggtgattgtgatcatc
tcacttattgtcctggttgtcatttggaaacagaaaccgaggtatgaaattcgctggagg
gtcattgaatcaatcagcccagatggacatgaatatatttatgtggacccgatgcagctg
ccttatgactcaagatgggagtttccaagagatggactagtgcttggtcgggtcttgggg
tctggagcgtttgggaaggtggttgaaggaacagcctatggattaagccggtcccaacct
gtcatgaaagttgcagtgaagatgctaaaacccacggccagatccagtgaaaaacaagct
ctcatgtctgaactgaagataatgactcacctggggccacatttgaacattgtaaacttg
ctgggagcctgcaccaagtcaggccccatttacatcatcacagagtattgcttctatgga
gatttggtcaactatttgcataagaatagggatagcttcctgagccaccacccagagaag
ccaaagaaagagctggatatctttggattgaaccctgctgatgaaagcacacggagctat
gttattttatcttttgaaaacaatggtgactacatggacatgaagcaggctgatactaca
cagtatgtccccatgctagaaaggaaagaggtttctaaatattccgacatccagagatca
ctctatgatcgtccagcctcatataagaagaaatctatgttagactcagaagtcaaaaac
ctcctttcagatgataactcagaaggccttactttattggatttgttgagcttcacctat
caagttgcccgaggaatggagtttttggcttcaaaaaattgtgtccaccgtgatctggct
gctcgcaacgtcctcctggcacaaggaaaaattgtgaagatctgtgactttggcctggcc
agagacatcatgcatgattcgaactatgtgtcgaaaggcagtacctttctgcccgtgaag
tggatggctcctgagagcatctttgacaacctctacaccacactgagtgatgtctggtct
tatggcattctgctctgggagatcttttcccttggtggcaccccttaccccggcatgatg
gtggattctactttctacaataagatcaagagtgggtaccggatggccaagcctgaccac
gctaccagtgaagtctacgagatcatggtgaaatgctggaacagtgagccggagaagaga
ccctccttttaccacctgagtgagattgtggagaatctgctgcctggacaatataaaaag
agttatgaaaaaattcacctggacttcctgaagagtgaccatcctgctgtggcacgcatg
cgtgtggactcagacaatgcatacattggtgtcacctacaaaaacgaggaagacaagctg
aaggactgggagggtggtctggatgagcagagactgagcgctgacagtggctacatcatt
cctctgcctgacattgaccctgtccctgaggaggaggacctgggcaagaggaacagacac
agctcgcagacctctgaagagagtgccattgagacgggttccagcagttccaccttcatc
aagagagaggacgagaccattgaagacatcgacatgatggatgacatcggcatagactct
tcagacctggtggaagacagcttcctgtaa

KEGG   Homo sapiens (human): 5159
Entry
5159              CDS       T01001                                 
Symbol
PDGFRB, CD140B, IBGC4, IMF1, JTK12, KOGS, PDGFR, PDGFR-1, PDGFR1, PENTT
Name
(RefSeq) platelet derived growth factor receptor beta
  KO
K05089  platelet-derived growth factor receptor beta [EC:2.7.10.1]
Organism
hsa  Homo sapiens (human)
Pathway
hsa01521  EGFR tyrosine kinase inhibitor resistance
hsa04010  MAPK signaling pathway
hsa04014  Ras signaling pathway
hsa04015  Rap1 signaling pathway
hsa04020  Calcium signaling pathway
hsa04072  Phospholipase D signaling pathway
hsa04151  PI3K-Akt signaling pathway
hsa04510  Focal adhesion
hsa04540  Gap junction
hsa04630  JAK-STAT signaling pathway
hsa04810  Regulation of actin cytoskeleton
hsa05165  Human papillomavirus infection
hsa05200  Pathways in cancer
hsa05206  MicroRNAs in cancer
hsa05214  Glioma
hsa05215  Prostate cancer
hsa05218  Melanoma
hsa05230  Central carbon metabolism in cancer
hsa05231  Choline metabolism in cancer
Network
nt06110  MAPK signaling (viruses and bacteria)
nt06114  PI3K signaling (viruses)
nt06166  Human papillomavirus (HPV)
nt06167  Human cytomegalovirus (HCMV)
nt06210  ERK signaling
nt06214  PI3K signaling
nt06220  Calcium signaling
nt06273  Glioma
  Element
N00015  PDGF-PDGFR-RAS-ERK signaling pathway
N00016  PDGF-overexpression to RAS-ERK signaling pathway
N00028  PDGF-PDGFR-PLCG-CAMK signaling pathway
N00039  PDGF-PDGFR-PI3K signaling pathway
N00368  HPV E5 to PDGFR-PI3K signaling pathway
N00369  HPV E5 to PDGFR-RAS-ERK signaling pathway
N00386  HCMV gB to PDGFR-RAS-ERK signaling pathway
Disease
H00042  Glioma
H01574  Familial idiopathic basal ganglia calcification
H01910  Infantile myofibromatosis
Drug target
Becaplermin: D03065<US>
Crenolanib (DG01361): D10102 D10103
Dasatinib (DG00714): D03658<JP> D06414<JP/US>
Dovitinib lactate: D08907
Ilorasertib: D10423
Linifanib: D09635
Midostaurin: D05029<US>
Motesanib (DG01262): D06678 D08947
Nilotinib (DG00716): D06413<JP/US> D08953
Nintedanib (DG01374): D10396<JP/US> D10481
Pazopanib: D05380<JP/US>
Regorafenib (DG00720): D10137<JP/US> D10138
Seralutinib: D12002
Sitravatinib (DG03045): D11140 D11541
Sorafenib (DG00713): D06272<JP/US> D08524
Sunitinib (DG00712): D06402<JP/US> D08552
Tandutinib: D06005
Tivozanib (DG01375): D10190<US>
Toceranib (DG01363): D08503 D08544
Vatalanib: D06285
Brite
KEGG Orthology (KO) [BR:hsa00001]
 09130 Environmental Information Processing
  09132 Signal transduction
   04010 MAPK signaling pathway
    5159 (PDGFRB)
   04014 Ras signaling pathway
    5159 (PDGFRB)
   04015 Rap1 signaling pathway
    5159 (PDGFRB)
   04630 JAK-STAT signaling pathway
    5159 (PDGFRB)
   04020 Calcium signaling pathway
    5159 (PDGFRB)
   04072 Phospholipase D signaling pathway
    5159 (PDGFRB)
   04151 PI3K-Akt signaling pathway
    5159 (PDGFRB)
 09140 Cellular Processes
  09144 Cellular community - eukaryotes
   04510 Focal adhesion
    5159 (PDGFRB)
   04540 Gap junction
    5159 (PDGFRB)
  09142 Cell motility
   04810 Regulation of actin cytoskeleton
    5159 (PDGFRB)
 09160 Human Diseases
  09161 Cancer: overview
   05200 Pathways in cancer
    5159 (PDGFRB)
   05206 MicroRNAs in cancer
    5159 (PDGFRB)
   05230 Central carbon metabolism in cancer
    5159 (PDGFRB)
   05231 Choline metabolism in cancer
    5159 (PDGFRB)
  09162 Cancer: specific types
   05214 Glioma
    5159 (PDGFRB)
   05218 Melanoma
    5159 (PDGFRB)
   05215 Prostate cancer
    5159 (PDGFRB)
  09172 Infectious disease: viral
   05165 Human papillomavirus infection
    5159 (PDGFRB)
  09176 Drug resistance: antineoplastic
   01521 EGFR tyrosine kinase inhibitor resistance
    5159 (PDGFRB)
 09180 Brite Hierarchies
  09181 Protein families: metabolism
   01001 Protein kinases [BR:hsa01001]
    5159 (PDGFRB)
  09183 Protein families: signaling and cellular processes
   04090 CD molecules [BR:hsa04090]
    5159 (PDGFRB)
Enzymes [BR:hsa01000]
 2. Transferases
  2.7  Transferring phosphorus-containing groups
   2.7.10  Protein-tyrosine kinases
    2.7.10.1  receptor protein-tyrosine kinase
     5159 (PDGFRB)
Protein kinases [BR:hsa01001]
 Receptor tyrosine kinases (RTK)
  PDGFR family [OT]
   5159 (PDGFRB)
CD molecules [BR:hsa04090]
 Proteins
  5159 (PDGFRB)
SSDB
Motif
Pfam: PK_Tyr_Ser-Thr Pkinase ig Ig_3 I-set Ig_2 V-set C1-set TrmE_N Haspin_kinase
Other DBs
NCBI-GeneID: 5159
NCBI-ProteinID: NP_002600
OMIM: 173410
HGNC: 8804
Ensembl: ENSG00000113721
Pharos: P09619(Tclin)
UniProt: P09619 Q59F04
Structure
LinkDB
Position
5:complement(150113839..150155845)
AA seq 1106 aa
MRLPGAMPALALKGELLLLSLLLLLEPQISQGLVVTPPGPELVLNVSSTFVLTCSGSAPV
VWERMSQEPPQEMAKAQDGTFSSVLTLTNLTGLDTGEYFCTHNDSRGLETDERKRLYIFV
PDPTVGFLPNDAEELFIFLTEITEITIPCRVTDPQLVVTLHEKKGDVALPVPYDHQRGFS
GIFEDRSYICKTTIGDREVDSDAYYVYRLQVSSINVSVNAVQTVVRQGENITLMCIVIGN
EVVNFEWTYPRKESGRLVEPVTDFLLDMPYHIRSILHIPSAELEDSGTYTCNVTESVNDH
QDEKAINITVVESGYVRLLGEVGTLQFAELHRSRTLQVVFEAYPPPTVLWFKDNRTLGDS
SAGEIALSTRNVSETRYVSELTLVRVKVAEAGHYTMRAFHEDAEVQLSFQLQINVPVRVL
ELSESHPDSGEQTVRCRGRGMPQPNIIWSACRDLKRCPRELPPTLLGNSSEEESQLETNV
TYWEEEQEFEVVSTLRLQHVDRPLSVRCTLRNAVGQDTQEVIVVPHSLPFKVVVISAILA
LVVLTIISLIILIMLWQKKPRYEIRWKVIESVSSDGHEYIYVDPMQLPYDSTWELPRDQL
VLGRTLGSGAFGQVVEATAHGLSHSQATMKVAVKMLKSTARSSEKQALMSELKIMSHLGP
HLNVVNLLGACTKGGPIYIITEYCRYGDLVDYLHRNKHTFLQHHSDKRRPPSAELYSNAL
PVGLPLPSHVSLTGESDGGYMDMSKDESVDYVPMLDMKGDVKYADIESSNYMAPYDNYVP
SAPERTCRATLINESPVLSYMDLVGFSYQVANGMEFLASKNCVHRDLAARNVLICEGKLV
KICDFGLARDIMRDSNYISKGSTFLPLKWMAPESIFNSLYTTLSDVWSFGILLWEIFTLG
GTPYPELPMNEQFYNAIKRGYRMAQPAHASDEIYEIMQKCWEEKFEIRPPFSQLVLLLER
LLGEGYKKKYQQVDEEFLRSDHPAILRSQARLPGFHGLRSPLDTSSVLYTAVQPNEGDND
YIIPLPDPKPEVADEGPLEGSPSLASSTLNEVNTSSTISCDSPLEPQDEPEPEPQLELQV
EPEPELEQLPDSGCPAPRAEAEDSFL
NT seq 3321 nt   +upstreamnt  +downstreamnt
atgcggcttccgggtgcgatgccagctctggccctcaaaggcgagctgctgttgctgtct
ctcctgttacttctggaaccacagatctctcagggcctggtcgtcacacccccggggcca
gagcttgtcctcaatgtctccagcaccttcgttctgacctgctcgggttcagctccggtg
gtgtgggaacggatgtcccaggagcccccacaggaaatggccaaggcccaggatggcacc
ttctccagcgtgctcacactgaccaacctcactgggctagacacgggagaatacttttgc
acccacaatgactcccgtggactggagaccgatgagcggaaacggctctacatctttgtg
ccagatcccaccgtgggcttcctccctaatgatgccgaggaactattcatctttctcacg
gaaataactgagatcaccattccatgccgagtaacagacccacagctggtggtgacactg
cacgagaagaaaggggacgttgcactgcctgtcccctatgatcaccaacgtggcttttct
ggtatctttgaggacagaagctacatctgcaaaaccaccattggggacagggaggtggat
tctgatgcctactatgtctacagactccaggtgtcatccatcaacgtctctgtgaacgca
gtgcagactgtggtccgccagggtgagaacatcaccctcatgtgcattgtgatcgggaat
gaggtggtcaacttcgagtggacatacccccgcaaagaaagtgggcggctggtggagccg
gtgactgacttcctcttggatatgccttaccacatccgctccatcctgcacatccccagt
gccgagttagaagactcggggacctacacctgcaatgtgacggagagtgtgaatgaccat
caggatgaaaaggccatcaacatcaccgtggttgagagcggctacgtgcggctcctggga
gaggtgggcacactacaatttgctgagctgcatcggagccggacactgcaggtagtgttc
gaggcctacccaccgcccactgtcctgtggttcaaagacaaccgcaccctgggcgactcc
agcgctggcgaaatcgccctgtccacgcgcaacgtgtcggagacccggtatgtgtcagag
ctgacactggttcgcgtgaaggtggcagaggctggccactacaccatgcgggccttccat
gaggatgctgaggtccagctctccttccagctacagatcaatgtccctgtccgagtgctg
gagctaagtgagagccaccctgacagtggggaacagacagtccgctgtcgtggccggggc
atgccccagccgaacatcatctggtctgcctgcagagacctcaaaaggtgtccacgtgag
ctgccgcccacgctgctggggaacagttccgaagaggagagccagctggagactaacgtg
acgtactgggaggaggagcaggagtttgaggtggtgagcacactgcgtctgcagcacgtg
gatcggccactgtcggtgcgctgcacgctgcgcaacgctgtgggccaggacacgcaggag
gtcatcgtggtgccacactccttgccctttaaggtggtggtgatctcagccatcctggcc
ctggtggtgctcaccatcatctcccttatcatcctcatcatgctttggcagaagaagcca
cgttacgagatccgatggaaggtgattgagtctgtgagctctgacggccatgagtacatc
tacgtggaccccatgcagctgccctatgactccacgtgggagctgccgcgggaccagctt
gtgctgggacgcaccctcggctctggggcctttgggcaggtggtggaggccacggctcat
ggcctgagccattctcaggccacgatgaaagtggccgtcaagatgcttaaatccacagcc
cgcagcagtgagaagcaagcccttatgtcggagctgaagatcatgagtcaccttgggccc
cacctgaacgtggtcaacctgttgggggcctgcaccaaaggaggacccatctatatcatc
actgagtactgccgctacggagacctggtggactacctgcaccgcaacaaacacaccttc
ctgcagcaccactccgacaagcgccgcccgcccagcgcggagctctacagcaatgctctg
cccgttgggctccccctgcccagccatgtgtccttgaccggggagagcgacggtggctac
atggacatgagcaaggacgagtcggtggactatgtgcccatgctggacatgaaaggagac
gtcaaatatgcagacatcgagtcctccaactacatggccccttacgataactacgttccc
tctgcccctgagaggacctgccgagcaactttgatcaacgagtctccagtgctaagctac
atggacctcgtgggcttcagctaccaggtggccaatggcatggagtttctggcctccaag
aactgcgtccacagagacctggcggctaggaacgtgctcatctgtgaaggcaagctggtc
aagatctgtgactttggcctggctcgagacatcatgcgggactcgaattacatctccaaa
ggcagcacctttttgcctttaaagtggatggctccggagagcatcttcaacagcctctac
accaccctgagcgacgtgtggtccttcgggatcctgctctgggagatcttcaccttgggt
ggcaccccttacccagagctgcccatgaacgagcagttctacaatgccatcaaacggggt
taccgcatggcccagcctgcccatgcctccgacgagatctatgagatcatgcagaagtgc
tgggaagagaagtttgagattcggccccccttctcccagctggtgctgcttctcgagaga
ctgttgggcgaaggttacaaaaagaagtaccagcaggtggatgaggagtttctgaggagt
gaccacccagccatccttcggtcccaggcccgcttgcctgggttccatggcctccgatct
cccctggacaccagctccgtcctctatactgccgtgcagcccaatgagggtgacaacgac
tatatcatccccctgcctgaccccaaacccgaggttgctgacgagggcccactggagggt
tcccccagcctagccagctccaccctgaatgaagtcaacacctcctcaaccatctcctgt
gacagccccctggagccccaggacgaaccagagccagagccccagcttgagctccaggtg
gagccggagccagagctggaacagttgccggattcggggtgccctgcgcctcgggcggaa
gcagaggatagcttcctgtag

DBGET integrated database retrieval system